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 ABSTRACT 
 
Low back pain (LBP) is one of the major hazards to mankind. Now a days 
people sit early morning at lavatory and end up their day sitting in the dining table 
for dinner. They have not time to walk or take a nap. Some people toil all through 
the day standing and bending. They have no time to sit or sleep. This ultimately 
results in low back pain which affects approximately 60%-85% of adults. Low 
back pain which is the chief complaint of Thandaga Vatham, mentioned in Siddha 
text book Yugi Vaidhya Cinthamani-800, which is correlated with the clinical 
features of Lumbar spondylosis has become a major problem today, despite of 
many advances in treatment. Conventional medicines and surgical treatments end 
up with side effects and leave with defect and detriment like recurrence of pain, 
disability & nerve root damage. 
 
This study is concerned with ‘A Prospective open labelled non randomised 
Phase-II Clinical trial to assess the therapeutic efficacy of the siddha formulation 
MUNNAI ILAI KUDINEER for the treatment of THANDAGA VATHAM 
(LUMBAR SPONDYLOSIS)’, described in Gunapadam Mooligai Vaguppu Part-I 
text book to detect whether any significant improvements and relief can be done. 
Totally 40 patients with Thandaga Vatham (20 In patients, 20 Out patients of both 
sex) were selected randomly from OPD of Pothu Maruthuvam, Govt. Siddha 
Medical College, Tirunelveli, Tamil Nadu. They were given Munnai Ilai Kudineer 
30ml twice a day for 30 days. After the course of treatment majority of cases 
showed good response which is statistically significant. 
 
Keywords: 
Thandaga Vatham, Lumbar Spondolysis, Munnai Ilai Kudineer, Cardinal Signs, 
Range of motion, Back Pain Functional Scale Score (BPFSS). 
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CHAPTER-I 
INTRODUCTION 
The siddha system is one of the ancient systems of medicine.This system 
hasbeen cured various disease, including Mukkutra noigal, Peru noigal, Gunmam, 
Auto immune disorders and skin diseases.The fundamental and classical features of 
siddha treatment is  to  destroy the root cause of the diseases and it will  strengthen the 
body, mind and soul.Siddha system of  medicine is  not only cure diseases but also 
has preventive and rejuvenation of the health .Siddha system of medicine differs from 
other systems, because the etiology  management and of diseases. The main objective 
of the treatment is to equilibrium of three humours, namely Vatham, Pithamand 
Kapam.The cretantials of treatment is based upon balancing the three humours.The 
disturbances of the vatham which may be reduced or  exaggerated  lead to vatha 
diseases. 
The YUGI VAITHIYA CHINTHAMANI-800 is classified into 4448 types. 
Among 4448 diseases the Vatha diseases are 80 types and Pitha diseases are 42 and 
kapamdiseases are 21 types. Thefive elements (Pnachabootha panchikarnams) possess 
two properties viz., subtle and gross. These elements always act in mutual co-
ordination and can never act independently. The various proportions in which they 
combine give rise to different substances. Thus, this theory proposes that 96 basic 
factors exist, which is the basic concept underlying this holistic medical science. 
The human body formed by these 96 basic factors is conditioned mainly by 
Uyir thathukkal and Udal thathukkal.The 96 factors are the physical, physiological, 
psychological, intellectual aspects of every human. The five primordial elements 
manifest themselves as a human with these 96 basicfactors. 
Raw drugs are classified based on maintaining the three vital humours as 
Thavaram (Plants), Thathu (Metals and Minerals) and Jeevam Products (Animal 
Products).Further, drugs are  based on Suvai (Taste), Gunam (Character), Veeriyam 
(Potency) and Pirivu (Section). The thandaga vatham is one among the vatha 
disease,it was coming under the head of degenerative disease .The clinical symptoms 
and signs is similarly  corrlated in modern medicine  is , Lumbar spondylosis.   
In India, Lumbar spondylosis affects 60%-85% of the adults during some 
point in their lives. 84% of men and 74% of women are suffering from Lumbar 
spondylosis in the age group of 45-64 years of population is prone to develop 
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disorders of vertebral column ,like lumbar spondylosis Prolapsed Intervertebral 
DiscPID),osteoporosis and the degenerative disease of spine.Majarity of them are 
suffering from PID or lumbar spondylosis. The clinical features of Lumbar 
spondylosis is Pain from the low back, sacroiliac region and ascend lower 
extremitiess The compersson of roots,can produced superficial and deep sensory 
symptoms. There is no proper medication available in other systems.But siddha 
system was mentioned in various text books and manuscript to treat the 
thantagavatham. This work  is to deals elaborately discussed about the etiology, 
pathology, clinical feature, external and internal treatment  and complications of 
Thandaga Vatham.So, the clinical trial drug “MUNNAI ILAI KUDINEER”  is 
mentioned in GUNAPADAM MOOLIGAI VAGUPPU PART-I is more effective 
to reduced back pain  and strengthen the para spinal muscles.In review articles are 
proved  Munnaii Ilai has good anti-inflammatory, analgesic and anti-vatha activities 
and  pharmacological research also proved the  same. 
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CHAPTER-II 
AIM AND OBJECTIVES 
AIM: 
To evaluate the clinical and therapeutic efficacy of Munnai Ilai Kudineer in 
Thandaga Vatham (Lumbar Spondylosis). 
 
OBJECTIVES: 
Primary Objective: 
• To develop evidence support for the effect of Munnai Ilai Kudineer in 
ThandagaVatham. 
Secondary Objective: 
• To evaluate the Anti inflammatory and Analgesic Pharmacological activity of 
Munnai Ilai Kudineer. 
• To determine the safety profile of clinical trialdrugs. 
• To evaluate the Bio chemical analysis in Munnai ilia kudineer. 
• To survey the incidence of the disease, according to Age, Occupation, Socio 
Economic Status, Habits, Family History, Paruva Kaalangal, Thinai and Three 
Vital Humours. 
• To evaluate the changes in the Envagai thervugal in Thandaga Vatham 
according to Siddha basic concepts. 
• To carried out Modern parameter changes in Thandaga vatham (Lumbar 
Spondylosis). 
• To discuss about prognosis and treatment effect after end of the study. 
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CHAPTER-III 
REVIEW OF LITERATURE 
3.1 IN JOURNAL ASPECT: 
Anti inflammatory Activity 
Karthikeyan  and  Deepa. 2011  studied reports showed that the PCEE 
significantly inhibited the egg albumin induced edema and reduced granuloma 
formation in cotton pellet method and have preferable anti-inflammatory effect with 
long term administration. The phytochemical studies revealed the presence of β-
sitosterol and luteolin in leaves. The anti-inflammatory activity may be due to the 
presence of β-sitosterol or luteolin. Luteolin exerted the strongest blocking action on 
expression of this inflammatory mediator Luteolin, exerted inhibitory effects on TNF-
alpha, IL-6 and IFN-gamma production Luteolin suppressed TNFalpha-induced IL-8 
production in dose-dependent manner. 
Antihyperglycaemic activity 
Dash et al. 2005 was studied on antihyperglycaemic activity of Premna 
corymbosa reveal that the extract of the leaves showed significant antihyperglycaemic 
activity against alloxan induced diabetic rats, when compared with the controls. 
However, in normoglycaemic animals, there was not much marked decrease observed 
in the blood sugar level at tested dose levels. 
Hepatoprotective activity 
Karthikeyan and Deepa were studied the histopathology of the liver sections 
evidenced the hepatoprotective activity. The liver weight was reduced by the 
ethanolic extract treated groups.The ethanolic extract of the leaves of Premna 
corymbosa possess significant acute hepatoprotective activity. Premna corymbosa can 
be recommended for the liver disorders. 
Cardiac Stimulant Activity: 
Rajendran et al. 2008 Cardiac stimulant activity was reported for water and 
ethanol extract of bark and wood of Premna corymbosa. The ethanol extract 
produced significant positive ionotropic effects similar to that of Digoxin.  
A significant decrease in membrane Na+K +ATPase and Mg2+ ATP ase and 
significant positive ionotropic and chronotropic effects similar to that of Adrenaline. 
It was concluded that the ethanol extract produced cardiotonic effect and the aqueous 
extract produced adrenergic effect. 
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Antitumor Activity: 
Serrame and Limsylianco.1995 Anti-tumor promoting activity of decoctions 
and expressed juices from some philippinel medicinal plants including Premna 
corymbosa was evaluated. Significant inhibition of growth of tumours was shown by 
Premna corymbosa . 
Antibacterial Activity: 
Anbazhakan and Bahu, 2007 Studied showed Antibacterial activity of hexane, 
chloroform, ethyl alcohol and water extracts and water extracts of the stem bark of 
Premna corymbosa was done and it was reported that chloroform extract of the root 
inhibited the growth of Entero bacteraero genes but there was no activity on the other 
extracts. The presence of Di-C-glycosyl flavones in the heart wood of plant might be 
the reason for antibacterial activity. Also all the extracts were active against 
Alkaligens faecalis, Bacillus subtilis and Eischeria coli . 
Diuretic Activity: 
Anbazhakan and Babu, 2007 was studied Alcoholic extract of roots of Premna 
latifolia was found to show diuretic activity. The urine output was more in rats treated 
with 1mg/kg and 2mg/kg body weight and also in dogs treated with 2mg/kg than the 
control group. The mechanism of action was thought to be direct vasodilator effect 
(Rema and Vijayamma, 1995).A study on indigenous knowledge of Premna 
tomentosa was done. It of was concluded that leaves this plant has diuretic properties 
and can be used in dropsy treatment. Also an extract of inner bark was used to arrest 
diarrhea and the decoction of root can be given in stomachache. It was also used by 
people for curing rheumatism, liver and spleen disorders and joint pains . 
Antiparasitic Activity: 
Desrivit et al. 2007 was done antiparasitic activity of some new caldonian 
medicinal plants including Premna corymbosa were evaluated. It was observed that 
Premna serratifolia was active against Leishmania donovani with IC50 values 
between 0.5- 5µg/ml . 
 
 
 
 
 
 
 3.2 IN SIDDHA LITERATURE
3.2.1     IN GUNAPADAM ASPECT
Tamil name : Munnai 
Other names : Arani, Vaisayanthi
Suvai  : Thuvarpu, Kaippu
Thanmai : Veppam 
Privu  : Karppu 
Part used : Ilai, Ver 
Actions 
1.
 Stomachic 
2.
 Carminative 
3.
 Alternative 
4.
 Tonic 
 
     FIGURE-1                                                                   FIGURE
 
Tamil 
Name 
Botanical Name
(Family) 
Leaves 
of 
Munnai 
Prema 
corymbosa 
(VERBENACEA
E) 
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- MUNNAI 
 
 
 
-2 
 Phytochemicals Action Therapeutic 
uses
Verbascoside, 
Iridoid 
glycoside 
Premcoryoside 
Premnine 
,Premnazole 
Premnenol 
Premna 
spirodiene . 
Anti- 
inflammator
y, Anti-
oxidant, 
Anti-
analgesic 
Vatha disease
 
Amount 
 7.5gms 
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3.2.2  SIDDHA ASPECTS: 
The concept of Siddha system of medicine is based on 96 Thathuvangal which 
is made up of five primordial basic elements.Among which the three vital humours, 
Arusuvaigal and udal thathukkal play an important role.The vatham is mainly affected 
in in thandagavatham.Vatham is characteristic by vayu, dryness, pain, flatulence, 
sensitiveness, lightness, and also air. 
Vatham has a vital role in locomotion (or) movement activity. If Vatham is 
disturbed, locomotion is affected. The other two humours are deranged on severity of 
disease. Thus in Noi Naadal and Noi Mudhal Naadal Part-I text book clearly explains 
Vatham is soverign. It is called as Pranam, of living beings. 
uiklib<!hjmk<K!
hqk<k!ue<eqbib<!gik<K!
sqOzk<Kl!sQklib<!Kjmk<K!
.!Ofib<!fimz<!Ofib<!Lkz<!fimz<!kqvm<M< < < < < << < < < < << < < < < < !
)higl<.2?!hg<gl<!w{</:8*!
The Vatha dosham quoted in various Siddha literature are as follows: 
According to Agasthiyar,  
gi{h<hi!uiklQxqz<!giz<jggt<!ohiVk<K!OfiUl<!
H,{h<hi!Gmz<!Hvm<Ml<!lzszl<!ohiVlqg<gm<Ml<! ! ! !
! ! ! ! ! ! .!ngk<kqbI!juk<kqb!giuqbl<!2611< < << < << < < !
! ! ! ! ! ! )himz<!w{</21?!hg<gl<!w{</3*!
According to Thirumoolar, 
 wxqb!fz<uikl<!wxqg<Gl<!G{r<OgT!
Gxqobeg<!jggiz<!Gjts<S!uqzis<!sf<K!!
! Hxqobe!ofif<Kmz<!hs<jsh<H{<!NGOl!
! ! ! ! ! ! .!kqV&zI!gVg<gqjm!juk<kqbl<< < << < << < <.711!
! ! ! ! ! ! )himz<!w{</47?!hg<gl<!w{</22*!
According to Theriyar, 
kg<guiB!Ogihqk<kiz<!sf<KUjtf<K!kjzOfiui!
! lqg<g!&iq!ogim<miuq!uqm<mr<ogiqB!lzr<gm<Ml<!
! yg<gfvl<H!kie<Lmr<G!LzIf<K!uib<fQ'xquVl<! ! ! !
! ! ! ! ! ! .!OkjvbI!uigml<<<<!
! ! ! ! ! ! )himz<!w{</3?!hg<gl<!w{</24*!
!
!
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uikuQX!ne<elqxr<giK!gMh<H{<mil<!u{<{L{<mil<!
OliKgm<MOvigl<!SvL{<mi!lqVlZli!Lxr<gioke<Xl<!
yK$iqb!uikleziG!fMg<gL{<mil<!ohiVt<gtib<f<!
kQokeOu!fvl<hqsqk<K!sf<Kgt<OkiXl<!gMg<Gf<!kqeLf<kiOe!
! ! ! ! ! .!OkjvbI!uigml<<<<!
! ! ! ! ! ! )himz<!w{</321?!hg<gl<!w{</69*!
According to Sivavakiyar, Vatham is Omnipotent. It is the beginning, 
benevolent, soverign, eminent diety.  It has the character to form other twocombained  
humours. 
 uiklie!OkuOe!bikqbigq!fqe<xue<!
! uiklie!OkuOe!jubgl!jlk<kue<!
! uiklie!OkuOe!bXokipqz<!uGk<kue<!
! uiklie!OkuOe!u{<jl!g{<M!%XOl!
! ! ! ! ! ! .!squ!uig<gqbI!fic<<< !
The Vatham is  primary deranged and further secondary  Pitham and Kapam 
gets affected  
uiklqG!G{l<;<<< !
nxqbuql<!&e<xqe<!ke<jl!osie<eiIff<kq!
Wxqb!fz<uik!olxqg<Gr<!G{r<OgT!
Gxqobeg<!jggiz<!Gjts<S!uqzis<sf<K!
! ! ! ! ! ! .!kqV&zI!gVg<gqjm!juk<kqbl<< < << < << < <.711!
!
uikuQX!ne<elqxr<!giK!gMh<H{<mil<!u{<{L{<mil<!
OliKgm<G!Ovigl<!SvL{<mi!lqVlZlv!Lxr<gioke<Xl<!
YKkiqb!uikleziG!fMg<gL{<mil<!ohiVt<!gtbIf<k!
kQokeOu!fvl<hqk<K!sf<Kgt<!OkiXr<!gMg<Gf<!kqeLf<kiOe!
! ! ! ! ! ! .!OkjvbI!uigml<<<<!
! ! ! ! ! !!! )himz<!w{</321?!hg<gl<!w{</69*!
kg<guiB!Ogihqk<kiz<!sf<Kjtk<K!$jzOfiui!
lqg<g!ogim<miuq!uqm<mr<!ogiqB!lzr<ogm<Ml<!
yg<g!fvl<Hkie<!Lmr<G!lzIf<K!uib<!fQ'xquVl<!
lqg<g!GtqVl<!fMg<glib<!Oleq!Ge<xq!uVr<giOe!
! ! ! ! ! ! .!OkjvbI!uigml<<<<!
! ! ! ! ! ! )himz<!w{</54?!hg<gl<!w{</24*!
!
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uikl<! lqGl<! OhiK! hsqbqe<jl?! dmz<! gMh<H?! Svl<?! -Vlz<?!
dxg<glqe<jl?! Svl<! fMg<gl<?! fvl<Hk<! ktIs<sq?sf<Kgt<OkiXl<! Gjmkz<?!< < < << < < << < < <
uqzis<sf<Kgt<! Ofikz<?< < < << < < << < < < ! ubqX! ohiVlz<?! Gmzqjxs<sz<?! lzs<sqg<gz<?! lqGf<k!
ogim<miuq!Ohie<x!GxqG{r<gt<!Okie<Xl/</!
According to Siddha Maruthuvanga Churukkam, Yugi Munivar says, the 
Vatham  islives from Abanan (Pelvic plexus),Idakalai, Umblical cord, Skin, Joints, 
Motion, Lower abdomen, Hipbones, Nerves, Hair follicles and Muscles.It was 
mentioned Siddha maruthuvanga chrukkam in below lines,  
fiole<x!uikk<Kg<!gqVh<hqmOl!Ogtib<!
fihqg<Gg<!gQope<X!fuqz!ziGl<!
! ! ! ! ! ! .!sqk<k!lVk<Kuir<g!SVg<gl<!< < < < << < < < << < < < < !
)hg<gl<!w{</251*!
3.3.THANDAGA VATHAM 
SYNONYMS: 
 k{<Muikl<?!-Mh<H!uikl<!)uik!Ofib<!lVk<Kul<?!hg<gl<!w{</225?!237*!
DEFINITION: 
 Thandaga Vatham is a  clinicalcondition which is characterized by great 
prostration, in which the body is rendered like a log of wood, unable to stretch or fold 
the limband passed  motion or urine.  The whole body assumes rigidity as the stiffness 
appearing after death. (T.V.sil<hsqul<!hqt<jt?!ngvikq!higl<-IV) 
AETIOLOGY: 
The factors that play its role in modification of Vatham are, 
• Environmental factors 
• Physical Factors 
•  Factors of Kanmam 
1) Environmental factors (Seasonal Variations):  
 Ncbikqbib<!Jh<hsq=xib<!
! Neqzlkx<!Ogivvsqbz<!gizl<!
! ! ! ! ! ! .!skgfic!)Ofib<!fimz<!!
Ofib<!Lkz<!fimz<!higl<.I*!
! ! ! ! ! ! )hg<gl<!w{</167, 168*!
The Sathaga Naadi described, the Vatha disease get predominant in the 
month of Aadi to Iypasi (July to November). 
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uik!uIk<kje!gizOlOki!oue<eqz<!
lVUgqe<x!Neq!gx<gmgliGl<!
Nkjuh<!hsqObiM!giIk<kqjg!ke<eqz<!
nVmOl//////////////////////////////////////////////////////!
! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < !
! ! ! ! !!! )himz<!w{</356?!hg<gl<!w{</87*!
 According to Yugi Vaidhya Chinthamani-800 discribed the  Vatham is  
provoked in its own site in the month of Iypasi and Karthigai (Oux<X!fqjz!utIs<sq) 
and retains normal in the rest of the month (ke<eqjz!njmkz<). 
hKlk<jkh<!h,g<g!jug<Gl<!hiElqg<g!giBl<!
!! LKOueq!zqx<H!uqfQI!Lx<Xl<!.!gKole!
! ux<Xl<!ghGl<!uiBlqGl<!/////////////////////////////////////!
! ! ! ! ! ! .!lVk<Ku!keqh<himz<< < << < << < <! !
 Olx<%xqb! himzqe<! &zl<! LKOueqx<! gizk<kqz<?! $iqb! ouh<hk<kqe<!
giv{lig!ohVuiiqbig!fQI!Nuqbig<gh<hm<M!h,lqbqz<!uxm<sq!fqzUl</!nKOhiz<!
flK!dmzqz<!uxm<sq!Wx<hm<M!utq!Ofib<!uVukx<G!giv{ligqxK/!
2) Physical factors: 
1). According to Sabapathy Manuscript is explained, 
 utqkV!gib<gqpr<G!ujvuqzi!kbqzz<!Ogijp!
! LtqkV!Ohie<lqGg<G!Ljxbqzi!u{<c!Ogimz<!
! GtqIkV!utqbqx<!Okgr<Gtqh<Hx!Uzuz<!oh{<cI!
! gtqkV!lbg<gl<!ohx<OxiI!gcosbz<!gVuqbiliz!
! ! ! ! ! .!shihkq!jgObM.sqk<klVk<Kul<!)ohiK*< < << < << < < !
! ! ! ! ! )hg<gl<!w{</735*!
The above poem was explained, the  Excessive oral  intake of rhizomes and 
vegetables can  are increased  Vatha diseases.  Irregular food intake, prolonged 
exposure to cold air, staying in hilly area, excessive sexual activity and hereditary 
factors also to produced the Vatha diseases. 
2). According to Noi Naadal and Noi Mudhal Naadal Part-I, text  
 Sour and Astringent food stuffs increases the Vatha disease. 
 lik<kqb!Htqh<H!lQxqz<!uf<kqMl<!uikliGl<!
! Osk<Klf<!k{<{QI!hqk<kf<!kQ!gix<X!uikliOl!
! ! ! ! ! ! )ngk<kqbI!fic*!
! ! ! ! ! ! .!Ofib<!fimz<!Ofib<!Lkz<!fimz<< < < < << < < < << < < < <!
! ! ! ! ! !! )higl<.I,!hg<gl<!w{</33*!
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Intake of large amount of sour foods increases Vatham. 
 uikOl!Htqh<H!Ou{<Ml<!ue<hqk<kr<!gsh<H!Ou{<Ml<!
! kQkqzisq!Ozx<hef<kie<!OsIf<kqMl<!-eqh<H!Ou{<Ml<!
! Ykqb!uik!hqk<k!sqOzx<he!okif<kk<!OkiIg<Gg<!!
! gikzib<k<!KuIk<kz<!givz<!duIh<OhiM!gVKr<giO{!
! ! ! ! ! ! )-vk<kqes<!SVg<g!fic*!
! ! ! ! ! ! .!Ofib<!fimz<!Ofib<!Lkz<!fimz<< < < < << < < < << < < < <!
! ! ! ! ! !!! )higl<.I,!hg<gl<!w{</33*! !
 The sour foods would definitely increased  the Vatham while astringent foods 
are added unto it. 
3). According to Yugi Muni in Yugi Vaithya Chinthamani-800. 
 hgvOu!uiklK!Ogihqk<kh<Ohi!
! h{<hig!oh{<Ohigl<!nKkie<!osb<bqz<!
! fgvOu!ouGK~v!upq!fmg<gqz<!
! ftqvie!gix<XOl!heqOlz<!hm<miz<!
! lqgvOu!gib<gt<!geqgqpr<G!ke<je!!
! lqguVf<kq!lQxqOb!kbqIkie<!ogi{<miz<!
! LgvOu!LKogZl<jh!LXg<gq!ofif<K!
! Lpr<giZl<?!g[g<giZl<!gMh<H{<miOl!
! ! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < .911!
! ! ! ! ! !!! )himz<!w{</285,!hg<gl<!w{</9:*!
 Excessive sexual activity (or) desire, walking for a long distance, prolongs 
exposure to cold extreme dampness, Intake of harmful food stuffs like excessive curd 
consumption after eating fruits, vegetables and tubers produce toxic factors which 
affect muscles and bones produce Vatha diseases. 
! we<eOu!uikf<ki!ou{<hkiGl<!
! -gk<kqOz!leqkIgTg<!ogb<BliX!
! hqe<eOu!oh{<kjeOb!OsivR<osb<K!
! ohiqObiIgt<!hqvil{jvk<!K~m{qk<Kl<!
! ue<e!Okus<!osik<kqz<!OsivR<!osb<K!
! liki!hqki!GVju!lxf<k!OhIg<Gl<!
! ge<eOu!Oukk<jk!fqf<jk!osb<kiz<!
! gibk<kqx<!gzf<KMOl!uikf<kiOe!
! ! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < .911!
        )himz<!w{</243,!hg<gl<!w{</87*!
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Breach of trust, abusing the pious, elderly people, priests and holy spirits, 
exploitation of charitable properties, ingratitude towards mother, father and teacher 
results in Vatha diseases. 
kioee<x!gsh<OhiM!KuIh<H!jgh<H!
! sikglib<!lqR<SgqEl<!sjlk<k!u{<{l<!
Noee<x!NxqeK!Hsqk<k!ziZl<!
Ngibk<!OkxzK!Gck<kziZl<!
hioee<x!hgZxg<g!lqviuqpqh<H!
hm<ceqOb!lqgUXkz<!hivolb<kz<!
Okoee<x!olipqbiI!Olx<sqf<jk!bikz<!
sQg<gqvlib<!uiklK!oseqg<Gf<kiOe!
! ! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < .911!
! ! ! ! ! ! )himz<!w{</244,!hg<gl<!w{</87*!
 Excessive intake of bitter, astringent and salty foods, intake of dry and old 
cooked rice, drinking polluted rain water, irregular sleep patterns, undue starving, 
excessive weight lifting and sexual perversion can induced Vatha diseases. 
! Neie!uxe<!xe<jeOb!lkqbi!lif<kI!
! ngkq!hvOksqbI!gm<!ge<e!lQbiI!
! Ogieie!GVolipqjb!lxf<kOhIgt<!
! ogijzgtU!ohib<lr<!Gxqk<k!OhIg<G!
! dteie!smf<ke<eqz<!uikl<!uf<K!
! dmx<huqg<Gl<!Oukk<kq!Z{<jl!kiOe!
! ! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < .911!
! ! ! ! ! ! )himz<!w{</253,!hg<gl<!w{</:6*!
Disobedience attitude towards God, refusing food for destitute and 
Sanyasi,disagreeing the advice of preceptors, engage in murdering, stealing, unjustice 
and speaking lie leads to Vatha diseases. 
4). According to Theraiyar in Theraiyar Vagadam text,  
oub<bqzqz<!fmg<jgbiZl<!lqgk<!k{<{QI!Gcg<jgbiZl<!
Osb<bqjp!lgtqjvs<!OsIf<ke!hzqg<jgbiZl<!
jhbOe!d{<jlbiZl<!higx<gib<!kqe<jgbiZl<!
jkbOz!uikOvigl<!seqg<G!ole<xxqf<K!ogit<t!
! ! ! ! ! ! .!OkjvbI!uigml<<<<!
! ! ! ! ! !!! )himz<!w{</16,!hg<gl<!w{</6*!
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 Excessive walking in hot sun, excessive intake of water, excessive sexual 
activity, intake of bitter guard may disturb the normal functions of Vatham. 
5). According to Pararasa Sagaram, 
okipqz<ohX!jgh<Hg<!giIk<kz<!KuIk<kz<!uqR<SgqER<!OsiXl<!
hjpbkil<!uvG!lx<jxh<!jhf<kqj{!bVf<kq!eiZl<!
wpqz<ohxh<!hgZ!xr<gq!-vuqeq!zxr<gi!kiZl<!!
ljpfqgI!Gpz!eiOt!uikr<Ogi!hqg<Gr<!giO{!
Improper dietary habits and sleep pattern can cause Vatha diseases. 
gizr<g{<!lixq!B{<[r<!giiqbk<!kiZf<!k{<{QI!
sizOu!bVf<kq!eiZR<!sf<kqbq!Zm<giIf<kiZl<!
uizuiI!Ljzfz<!ziOt!uikLx<!huqg<Gr<giOb!
! ! ! ! ! ! .!hvvis!Osgvgl<<<<!
Improper food schedule, intake of excessive water, sitting in the cold air 
during evening hours leads to Vatha diseases. 
hiiqeqx<!hbh<hm<miZl<!hzVme<!Ogihqk<kiZl<!
gioveg<!gVgqObicg<!gPlvk<K!vk<kqeiZl<!
WIohX!keK!ofR<sqe<!lqgk<Kg<g!ljmf<kqm<miZl<!
hiiqb!gix<xqeiZl<!hmiQEl<!uikr<gi[l<!
! ! ! ! ! ! .!hvvis!Osgvgl<<<<!
 Fear, angry, anxiety, stress, exposure to cool air cause Vatha diseases 
6). According to Agasthiyar in Agasthiyar Gunavagadam,  
uquvlmi!nskq!se<eq!&jt!OfiU!!
uqiquie!&jtbK!lqVKuigq!
nueqkeqz<!kqmligh<!OhiukiZl<!
nh<hOe!&k<kqv!G{<cg<gib<!uqbikqbiZl<!
kuLequI!kQIg<gig<jg!Olg!Ovigl<!
ke<jlBt<t!Lk<k{<M!ogicuqbikq!
nulqzih<!hiqs!fvl<hPk<kr<!g{<miz<!
n[Glmi!uikOfib<!NGl<hiOv!
! ! ! ! ! ! .!ngk<kqbI!G{uigml<< << << <!
 Fatigue, Epilepsy, Brain diseases, renal diseases, Genito urinary diseases, and 
Connective tissue disorders induce Vatha diseases. 
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c). Factors of Kanmam (Hereditary): 
 In Siddha system many diseases are said to be caused by Kanmam which 
means the deeds committed by an individual in his / her present and previous births. 
 According to Agasthiyar Kanma Kandam-300,  
F~oze<x!uikl<!uf<k!ujgkiOeK!
K{<jlbib<g<!ge<lk<kqe<!ujgjbg<!OgT!
gizqOz!Okie<xqbK!gMh<hOkK!
jggizqz<!Lpg<gqbK!uQg<glK!
OgizqOz!hMgqe<x!uqVm<slie!!
Gpf<jk!lvf<kje!oum<mz<!Olz<Okiz<sQuz<!
F~zqOz!sQu\f<K!giz<!Lxqk<kz<!
fz<zogil<H!kjpLxqk<kz<!fzqk<kz<!kiOe!
! ! ! ! ! ! .!ngk<kqbI!ge<lgi{<ml<< < < << < < << < < <!
! ! ! ! ! !!! )himz<!w{</56,!hg<gl<!w{</34*!
Vatha Kanma Varalaru is concludedthat the psychological factors such as 
removing the bark of living trees, injuring the animals, cutting the branches in the 
living trees and plucking the leaves may produceVatha diseases. 
OlZl<?!
nf<k{I!gx<H!likI!nVtqb!sihk<kiZl<!
Lf<kqb!uqjebiZl<!LkqIgIh<h!Olgk<kiZl<!
sqf<jkbqx<!ogiMjlbiZl<!squGV!fqf<jkbiZf<!
okif<klil<!uqbikqbiZl<!Okie<xqMl<!$jzkiOe!
Soolai (Stabbing pain) may occur by the curse of noble men and women, due 
to evil deeds in previous birth, due to the genito urinary diseases produced by their 
parents, due to bad thoughts and curse of Guru. 
CLINICAL FEATURES: 
uPk<kOu!&zikivk<jkh<!hx<xqOb!
lVuqOb!OlOzxq!LKG{<mikz<!
uqPk<kOu!sqvsqz<!uf<K!uqbIUligq!
uqGuig!Ofiuigq!Oleq!ge<eq!
hk<kOu!dml<ohr<Gl<!hR<S!Ohizil<!
hir<gie!lzsz!lR<stiGl<!
GPk<kOu!ok{<mlil<!uikf<ke<jeg<!
%xqOeir<!G{olz<zir<!%If<K!hiOv!
%If<kqm<m!lzszr<gt<!Kiqklieiz<!
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Ogi{<m!mg<gqh<!hqe<Hkie<!ogickib<!kt<tq!
DIf<kqm<m!siQvk<kq!Zkqv!lQxq!
Dxk<!Okb<k<K!kjzbkeq!oz{<o{b<!uiIg<gqz<!!
uiIk<kqm<m!upq!fmg<gqz<!olk<k!uf<kie<!
uikf<!kiEx<huqk<K!fjm!ogimilz<!
fiIf<kqm<m!fvl<OhiM!wZl<hqx<!$p<f<K!
f[gqOb!Obic!ofR<sq!OuXf<!kiOe!
! ! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < .911!
! ! ! ! ! !!!!)himz<!w{</288,289 hg<gl<!w{</109,110*!
Siddha review of literature describedabout the diseases Thandaga Vatham. 
i). According to Thanvanthri Vaidhyam, 
uiB!ukqglib<s<!sqOzx<hek<jkk<!!
kilgm<migs<!OsIk<Kk<!kck<kqMR<!siQvolz<zil<!
Ofilg<!gm<mie!Oleq!Fuzqjth<!ohbIh<Hk<!Okie<Xl<!
! kilg<!gm<mie!Ovigf<!k{<mg!uikliOl! !
! ! ! ! ! ! .!ke<uf<kqiq!juk<kqbl<< < < << < < << < < <!
 Thanvanthri,explains that in Thandaga Vatham,Vatham associated withKapam 
results in generalised edema, obesity and generalised debility. 
ii). According to Roganiganirnayasaram: 
“Okgl<!k{<mk<jk!Ohiz<!uqPf<K!njsuqz<zilz<!-Vg<Gl<”!
 Body is rendered like a log of wood. 
iii). According to Jeevaratchamirtham, 
uiBuieK! w{<o{b<! u^<K?! lf<k! u^<K?! sQk! uQiqb! u^<K?! kbqI?! nkqg!
zu{l<?!hgz<!fqk<kqjv?!hkqeie<G!Ougr<gjt!lxqk<kz<!Ngqb!-jugtqeiz<!
hqxf<k! sh<k! kiKg<gtqZl<! uqbihqk<K! njugjtg<! gjzk<K! uqm<M!
isb^<kiek<jk! nEsiqk<Ks<! sqOzk<Klhqk<kr<gjtk<! ke<Eme<! OsIk<Kg<!
ogi{<M! nubr<gtqe<! osbjz! lix<xq! uqMl</! -keiz<! vsikq! kiKg<gtqz<!
lvk<kz< (Numbness), sQktl< (Cold), dt<otiqs<sz< (Burning Sensation), siQvr<!
gek<kz< (Heaviness of body), Rihg! lxkq (Loss of Memory), hqvjl (Psychosis), 
nkqg! Oukje (Severe pain), fQIg<gm<M (Anuria) we<El< -g<GxqG{r<gOtiM!
OkglieK!k{<mk<jkh<!Ohiz!uqPf<K!njskZl<?!fQm<mZl<?!Lg<gZl<?!wPkZl<!
-z<zikqVg<Gl< (Body is rendered like a log wood and unable to flex, extend and 
rotate). 
.!nEOhig!juk<kqb!Okuvgsqbl<< << << <!
)Lkz<!higl<?!hg<gl<!w{</275*!
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iii). According to Sikitcharatna Deepam:  
 uiBuieK! &zikivk<jkh<! hx<xq! OlOzxq! LKgqzqVf<K! sqvsqz<! uf<K!
uqbIk<K!OfiB{<mig<gq!sIuir<gk<jkBl<! OfiBxs<! osb<uKme<!lzszl<!lR<st<!
uI{ligUl<?!Okgk<jk!k{<mgl<!Ohiz<!fQm<m!uqmilz<!osb<Bl</!!
∗ Profuse sweating all over the body 
∗ Yellow coloured urine 
∗ Body is found to be like a log of wood 
iv). According to Panditharatna Dr. S.Chidambaranatha Pillai, Siddha Medical 
Literature Research Centre, 
Idupu Vatham has the characterised features of pricking pain and generalised 
weekness,pain in the lower back area,restricted  spinal vertebrae motions.  
-Mh<hK!gMk<K!djtf<K!
! -jmuqmi!uzqk<Kg<!ogit<Tl<!
! LMg<glib<!GeqbOu!kie<!
! LMgqOb!fqlqv!ouim<miK!
! KMg<oge!uf<K!nmVl<!
! SvlK!nx<hl<!nx<hl<!
! Smg<oge!-Mh<jhs<!Sx<xq!
! siIf<kqMl<!uikl<!kiOe//////////!
! ! ! ! ! ! .!uikOfib<!lVk<Kul<< < << < << < <!
! ! ! ! !!! ! )hg<gl<!w{</225*!
The Idupu Vatham, pain aggrevates while walking and subsides at rest; while 
lying on bed, the patient is unable to move their lower back. 
OlZl<?!
fmh<ohe!OhiK!olk<k!fb<bOu!uzqg<Gole<e!
ogmh<oheOhiKl<!sx<Ox!G{ole!Okie<Xligqz<!
hMh<he!OhiKl<!bill<!higqbiz<!uikL{<mil<!
-Mh<ohe!OsVl<!uikk<kqbzqK!w{<[uQOv!
! ! ! ! ! ! .!uikOfib<!lVk<Kul<< < << < << < <!
! ! ! ! ! ! )hg<gl<!w{</225*!
OlZl<!!
 Thandaga Vatham, as described in Vatha Noi Maruthuvam , it was given 
below: 
Due to cold food stuffs, day time sleep, in case of Thandaga Vatham the 
patient develops increased level of Vatham their by deranging the Pitham and Kapam. 
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This leads to burning sensation (dt<!wiqs<sz<), psychosis (hqvjl) asthma )-jth<H* 
and severe pain )Oukje*. 
In Thandaga Vatham, the low back bone gets inflammed resulting in 
generalised debility, pain, body becomes weaker and patient gets anger easily. 
k{<M!uikk<kqe<!G{k<jk!six<xg<Ogitib<!lmlibqOz!
h{<Omk{<M!lqg!Dkq!hx<xqohiKlq!ogi{<cVg<Gl<!
uq{<Omil<!sqz!OhiKjtU{<mil<!lqGf<k!uim<mL{<mil<!
ogi{<Om!leLl<!ktIs<sqBl<!Ogih!lkqgl<gi[ole<Ox!
! ! ! ! ! ! .!uikOfib<!lVk<Kul<< < << < << < <!
! ! ! ! ! ! )hg<gl<!w{</237*!
Due to the changes in Uyir thathu specifically Vatham, the 96 thathuvangal 
gets affected.  As said above, due to various causes the following changes occurs in 
Thandaga Vatham.  
DIAGNOSIS IN SIDDHA: 
A). Piniyari Muraigal (Methods of Diagnosis) is based upon three main topic 
namely, 
 Poriyal Aridhal (Physical Examination, Perception) 
 Pulanal Aridhal (Palpation) 
 Vinadhal (Interrogation) 
i). Poriyal Aridhal (Inspection): 
 ‘Poriyal Aridhal’ means examining the five sense organs of perception. 
 
RiOef<kqiqbr<gtqe<!Nb<U< < < << < < << < < < !
Hze<gt<< << << <! okipqz<gt<< << << <! k{<mg!uikk<kqz<!< < << < << < < hikqh<H<<< !
Osuq! yzqb!nxqb!osb<b!! -bz<H!
olb<! dmzqz<!Dx<jx!nxqkz<! LKgqz<!uzq?!uQg<gl<!
g{<! ytqb!nxqbs<!osb<kz<! -bz<H!
fig<G! Sjujb!nxqbs<!osb<kz<! -bz<H!
&g<G! uisjejb!Fgvs<!osb<kz<! -bz<H!
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ge<Olf<kqiqbr<gtqz<!Nb<U< < < < << < < < << < < < < !
Hze<gt<< << << <! okipqz<gt<< << << <! k{<mg!uikk<kqz<!hikqh<H< < < << < < << < < < !
uib<! Ohss<!osb<Bl<! -bz<H!
Jg! -MkZl<?!Wx<xZl<!osb<Bl<! -bz<H!
giz<! fmg<gs<!osb<Bl<! giz<gtqz<!uzq!fmg<gs<!sqvll<!
wVuib<! lzk<jkg<!gpqg<Gl<! lzs<sqg<gz<!
gVuib<! gV?!Sg<gqzk<jkg<!gpqg<Gl<! -bz<H!
 
ii). Pulanal Aridhal (Palpation): 
 By examining the pulan i.e., the sense organ of the patient, the physician can 
able diagnose the disease. 
The five senses are,  
 Smell 
 Taste 
 Vision 
 Sensation of touch 
 Hearing 
iii). Vinadhal (Interrogation): 
 Vinadhal is questioning and gathering information regarding the previous 
history of disease and clinical features which are much essential for diagnosis. 
B). Envagai Thervugal (Eight Diagnostic Tools): 
The excellent and unique method in the Siddha system is the Envagai 
Thervugal. 
 fic!^<hiqsl<!fi!fqxl<!olipq!uqpq!!
! ! Lzl<!&k<kqvl<!lVk<KuviBkl<!
! ! ! ! ! ! .!Ofib<!fimz<!Ofib<!Lkz<!fimz<< < < < << < < < << < < < <!
! ! ! ! !! ! Lkz<!higl<!)hg<gl<!w{</381*!
1. Naadi (Pulse): 
Among the Envagai Thervugal, Naadi is most important. Naadi is felt as 
Vatham, Pitham and Kapam with the tip of the index, middle and ring fingers 
respectively over the lower end of the radius. 
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Normally Vatham, Pitham and Kapam are held in the ratio of 1:1/2:1/4. 
Derangement in this will reflect as disease. Naadi Nadai in Thandaga Vatham, 
kqVk<klil<!uikk<!OkiOm!kQr<ogiM!hqk<kR<!Osiqz<!!
ohiVk<K!gt<OkiXl<!ofif<K!OhikOu!hqcg<Gl<!$jz!
! ! ! ! ! .!Ofibqe<!sivl<!< << << < .!sqk<klVk<Kul<!)ohiK*< < << < << < < !
! ! ! ! !! )hg<gl<!w{</745*!
gi{h<hi!uik!lQxqz<!
! giz<jggt<!ohiVk<K!OfiGl<!
! ! ! ! ! .!giuqbfic!.!sqk<k!lVk<Kul<!)ohiK*< < << < << < < !
! ! ! ! !!! )hg<gl<!w{</745*!
! osiz<zqb!jubk<OkiM!hqk<kLr<!%cx<xieiz<!
!!!!!uz<zqbl<!Ohizg<!Gk<Kl<!jlf<kOe!wZl<H!OkiXl<!
! ! ! ! ! .!giuqbfic!.!sqk<k!lVk<Kul<!)ohiK*< < << < << < < !
! ! ! ! ! )hg<gl<!w{</745*!
nxqf<KhiI!uikOl!keqk<kiekiz<!!
siqf<kqmOu!giz<!Lmg<Gl<!
! ! ! ! ! .!ngk<kqbI!vk<kqes<!SVg<gl<< < < < << < < < << < < < <!
! ! ! !!! ! )hg<gl<!w{</745*!
uikk<kqz<!Osk<Klligqz<!uzqObiM!uQg<gL{<mil<!
! ! ! ! ! .!ngk<kqbI!fic<<< !
In Thandaga Vatham the following Naadi Nadai are commonly felt. 
 Vatham 
 Vatha Pitham 
 Pitha Vatham 
2. Sparisam (Sensation to touch): 
 Through Sparisam, heat or cold, smoothness, roughness, sweat, dryness of 
skin, patches, swelling, abnormal growth, ulcer, pain can be felt.  In Thandaga 
Vatham, heat, swelling, pain is found in some cases. 
3. Naa (Tongue): 
 In Thandaga Vatham, no abnormality is seen in Naa. 
4. Niram (Colour): 
 In Thandaga Vatham, some skin colour changes seen in affected area due to 
inflammatory mechanism. 
5. Mozhi (Voice): 
 In Thandaga Vatham, no abnormality is seen. 
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6. Vizhi (Eyes): 
 In Thandaga Vatham, no abnormality seen in vizhi. 
7. Malam (Faeces): 
 In Thandaga Vatham, Constipation is reported in some cases. 
8. Moothiram (Urine): 
 In urine, Neerkuri and Neikuri examinations are done. 
Neikuri (Oil Examination): 
The observation  the spreading oil  pattern  as follows: 
nvoue!fQ{<cen0Ok!uikl<!!
NpqOhix<!hvuqe<!n0Ok!hqk<kl<!!
Lk<okik<K!fqx<gqe<!olipqu!oke<!ghOl!
! ! ! ! ! ! .!Ofib<!fimz<!higl<< < << < << < <.2!
! ! ! ! ! )hg<gl<!w{</298,!3::*!
Neerkuri: 
 uf<k!fQIg<giq!objm!l{l<!Fjv!wR<soze<!
! jxf<kqbZtju!bjxGK!LjxOb!
.!sqk<k!lVk<Kuir<g!SVg<gl< < < << < < << < < < < << <<!
! ! ! ! !! ! )hg<gl<!w{</621*!
In urine examination the following characteristic features are observed 
namely. 
 Niram  - Colour 
 Edai  - Specific gravity 
 Manam - Smell  
 Nurai  - Frothy nature 
 Enjal  - Quality of urine voided 
 Apart from these, frequency of micturition, abnormal constituents such as 
sugar, protein, blood stains, pus, crystals also to be found out. 
In Thandaga Vatham, straw or hay coloured urine was noticed in Neerkuri. 
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C). Paruvakaalam (Seasonal variations): 
Sl. No. State of Kuttram Kaalam 
1. Vatham thannilai adaithal 
Munpani Kaalam, Pinpani 
Kaalam, Koothirkaalam, 
Elavenil Kaalam 
2. Vatham thannilai valarchi Muthuvenil Kaalam 
3. Vatham vetrunilai valarchi Karkaalam 
!
LKOueqx<!gizk<kqz<!flK!dmzqz<!uxm<sq!Wx<hm<M!utqOfib<!uVukx<G!
WKuigqxK/!
D). kqj{!)Geographical distribution*;!
GxqR<sq! ;! ljzBl<?!ljz!siIf<k!hGkqBl<!!
Lz<jz! ;! giMl<?!giM!siIf<k!hGkqBl<!
lVkl<!! ;! ubZl<?!ubz<!siIf<k!hGkqBl<!
ofb<kz<! ;! gmZl<?!gmz<!siIf<k!hGkqBl<!
hijz!! ;! l{Zl<?!l{z<!siIf<k!hGkqBl<!
! Lz<jz!lx<Xl<!ofb<kz<!fqzr<gtqz<!uik!Ofib<gt<!ohVltuqz<!Wx<hMl</!
E). WP!dmz<!kiKg<gtqe<!Nb<U< < < << < < << < < < !(Seven Udal thathukkal Examination):  
Sl. 
No. 
Udal 
Thathukkal 
Increased conditions 
Decreased 
conditions 
1. Saaram Loss of appetite, excessive salivation. 
Tiredness, fatigue, 
diminished 
activity of the 
sense organs. 
2. Senneer 
Boils and tumours in different parts of 
the body, spleenomegaly, colic pain, 
increased blood pressure, red eyes and 
skin, Jaundice, leprosy, Haematuria. 
Tiredness, 
Lassitude, 
Anemia. 
3. Oon 
Tumours or extra growth around the 
neck, face, abdomen, thigh, genitalia etc., 
with dyspnoea. 
Muscle wasting 
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4. Kozhuppu 
Tumours or extra growth around the neck, 
face abdomen, thigh, genitalia etc., with 
dyspnoea and loss of activity. 
Pain 
5. Enbu Extra growth of bone and teeth 
Weak bones, teeth, 
nails and hair. 
6. Moolai 
Heaviness, swollen eyes, swollen 
phalanges, oliguria and non-healing 
ulcers. 
Osteoporotic 
changes. 
7. 
Sukkilam 
or 
Suronitham 
Increased sexual activity and symptoms 
as that of urinary calculi. 
Infertility, pain in 
genitalia. 
 
In Thandaga Vatham: 
 Saaram, Seener, Kozhuppu, Enbu thathukkal are commonly affected. 
Saaram : Weakness, tiredness of body. 
Seener  : Early morning stiffness occurs in affected joints. 
Kozhuppu : Restricted movements in joints and reduced  
intervertebral disc. 
Enbu  : Produces degeneration in lumbar vertebrae, spondylotic  
changes and extra osteophytic formation  
F). Lg<Gx<xr<gtqe<!Nb<U< < < < << < < < << < < < <  (Mukkutram examination): 
Sl. 
No. 
Vatham Location Function 
In Thandaga 
Vatham 
1. Pranam Chest region 
Regulate respiration and 
controls the mental functions, 
functions of 
heart, lungs and brain 
Not Affected 
2. Abanam Pelvic region 
Control excretion such as 
sweating evacuation of stools, 
ejaculation of sperms, 
micturition, menstruation and 
parturition. 
May be 
Affected 
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3. Viyanan Nose and skull 
Helps in various movements of 
the body and responsible for 
nervous functions and 
Sensation 
Affected 
4. Uthanan Thorat 
Responsible for speech, 
vomiting hiccough , 
cough. 
Not affected 
5. Samanan Navel 
Regulates the digestion and 
controls all the other 
vayus. 
Affected 
6. Nagan Eyes 
Helps in opening and 
closing of the eyes, 
intelligence. 
Not affected 
7. Koorman Eye 
Responsible for vision, 
closure of eyelids. 
Not affected 
8. Kirukaran Saliva 
Secretion of saliva and mucous 
secretion in nasal 
cavity, helps concentration. 
May be affected 
9. Devathathan Ocular muscles 
It is responsible for laziness 
and eyeball 
movements 
May be affected 
10. Thananjeyan - It is responsible for 
degradation of body after death 
- 
 
Pitham: 
Sl. 
No. 
Pitham Functions 
In Thandaga 
Vatham 
1. Analagam Digestion May be affected 
2. Ranjagam Gives nutrition to blood May be affected 
3. Sathagam Responsible for wilful activities Affected 
4. Prasagam Gives luster to skin Not affected 
5. Alosagam Gives strength to eyes Not affected 
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Kapam: 
Sl. 
No. 
Kapam Functions 
In Thandaga 
Vatham 
1. Avalambagam Controls other Kapam Not affected 
2. Klethagam It lubricates the food May be affected 
3. Pothagam Responsible for taste sensation Not affected 
4. Tharpagam It acts as coolent for eyes Not affected 
5. Santhigam It maintains the integrity of joints Affected 
 
DIFFERENTIAL DIAGNOSIS: 
Thandaga Vatham is differential from the other  diseases, 
 
2/!NSukl<h!uikl<;< << << < !
uikli!Bmz<ouTk<K!upouz<!ziOfvl<!
lbg<gOli!cVlzi!b,jt!B{<mil<!
Ofklib<!ofR<sjmk<kh<!ohixq!gzr<Gl<!
ofVh<hig!dmz<gi[!ofM&s<S{<mil<!
OgiKkie<!lbg<gk<kqz<!lVf<kq!fQm<miz<!
GtqIs<sqbib<g<!Ogihqg<Gr<!%s<sZ{<mil<!
hikf<kie<!kqlqV{<mib<!Lm<OhiziGl<!
hMk<k!NSukl<hl<!hgvziOl!
! ! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < .911!
! ! ! ! !!! ! )himz<!w{</395?!hg<gl<!w{</219*!
The clinical features are: 
• Paleness of the body 
• Cough 
• Heaviness of chest 
• Numbness of both lower limbs 
• Pain present in  spino-vertebral column 
2. DVk<kl<h!uikl<;< < << < << < < !
Nole<x!uiklK!dt<t!mr<gq!
Nck<Kjmkie<!Gxr<gqv{<M!ltuib<h<!hx<xq!
giolex<!jggizqz<!uqvZ!Sx<xqg<!
gek<KOl!si{qbK!ohikqf<kiI!Ohizk<!
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Okole<x!sqvf<keqOz!hiv!L{<mib<k<!!
Okolr<G!&kqOb!kqlqV{<miGl<!
fiole<x!fmg<ogi{v!ouiMg<g!ligq!
fzqb,Vf<!kl<hlK!fEGr<giOe!
! ! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < .911!
! ! ! ! ! ! )himz<!w{</371?!hg<gl<!w{</:9*!
The clinical features are, 
• Heaviness in both thighs. 
• Feelings of cow dung applied over fingers of both hands and feet (Paraesthesia 
or Hypoaesthesia). 
• Whole body perceives numbness. 
• Difficulty in walking. 
3. uik^<kl<hl<;< < << < << < <  
dx<huqg<Gl<!uiklK!wPf<K!ohir<gq!
dbIgizqe<!Hxucjbg<!Gjmf<K!hx<xq!
okx<huqg<Gl<!uQg<glib<s<!osPl<h!Z{<mib<k<!!
Okgolr<Gl<!Ofiuigqk<!kqlqV!ligq!
uqx<Huqg<Gl<!uqz<ZOhiz!uqkeligq!
lqMg<gie!lif<kjeh<!Ohiz<!uqkeligq!
hx<huqg<Gl<!hve<xjeOb!fqjebi&I!
hMgqe<x!uik^<kl<!hLlil<!hiOv!
! ! ! ! ! ! .!b,gq!juk<kqb!sqf<kil{q< << << < .911!
! ! ! ! ! ! )himz<!w{</365?!hg<gl<!w{</:7*!
The clinical features are, 
 Dorsum of the feet gets affected (L5-S1), they look shining with edema, 
intense pain. 
 Whole body appears to be weak andfatigue. 
 Body is bend like abow. 
 Makes a strong built man to bend and bow whilewalking. 
 In Thandaga Vatham, diffuse low back pain, stiffness, radiating pain to lower limbs 
(Radiculopathy), yellow coloured stools and urine are present. 
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3.4    MODERN ASPECT 
LUMBAR SPONDYLOSIS 
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LUMBAR SPONDYLOSIS; 
 Lumbar Spondylosis is a form of lower back pain and is an important clinical, 
social, economic and public health problem affecting the worldwide population. It is a 
disorder with many possible etiologies and many definitions. 
DEFINITION: 
 Lumbar spondylosis changes in the spine are frequently referred to as 
osteoarthritis. For example, the phrase spondylosis of the lumbar spine  means 
degenerative changes such as osteoarthritis of the vertebral joints and degenerating 
intervertebral dicss(degenerative disc disease) in the low back. 
TACKLING THE TERMINOLOGY: 
The terms lumbar osteoarthritis, disk degeneration, degenerative disk disease, 
and spondylosis are used in the literature to describe anatomical changes to the 
vertebral bodies and intervertebral disc spaces that may be associated with clinical 
pain syndromes. Within the literature, lumbar spondylosis encompasses numerous 
associated pathologies including spinal stenosis, degenerative spondylolisthesis, 
osteoarthritis, spinal herniation and many others. 
EPIDEMIOLOGY: 
Age: 
The incidence of lumbar spondylosis is 27-37% of the asymptomatic lower 
back pain population. Worldwide, more than 80% of individuals older than 40 years 
have lumbar spondylosis, increasing from 3% of individuals aged 20-29 years. 
Approximately 84% of men and 74% of women have vertebral osteophytes, most 
frequently at T9-10 and L3 levels. Approximately 30% of men and 28% of women 
aged 55-64 years have lumbar osteophytes. Approximately 20% of men and 22% of 
women aged 45-64 years have lumbar osteophytes. 
Sex: 
Sex ratio reports have been variable but are essentially equal. Gender seems to 
be distinctly in the form of lumbar spondylosis, and disc space narrowing with or 
without osteophytes in women may be a risk factor for low back pain. 
LOCATION: 
Lumbar vertebrae is most frequently affected at the level of L4-S1 level. 
AETIOLOGY: 
Aetiology for this disorder was explained below 
 
28 
 
Degenerative Causes: 
There are primary and secondary causes 
a) Primary causes: 
• Genetic Factor 
• Manaul Labour 
• Metabolic Factor 
• Senility 
• Vicious attitude 
b) Secondary causes 
• Osteoarthritis 
• Rheumatoid arthritis 
• Metastatic carcinoma 
• Lymphoma of Spine 
• TB Spine 
• Road accidents 
• Accidental Injury 
• Old Lumbar Fracture 
• Past spine surgery 
• Acquired narrowing of lumbar spinal canal stenosis 
c) Occupational causes 
d)Hereditary Factors. 
Congenital narrowing of the cervical spinal canal (myelopathy is often seen 
when canals sagittal diameter is 12mm or less) 
Segmental defect-Hemi vertebra,Fushed vertebra. 
e) Past spine surgery 
f) Obesity 
g) Smoking-decrease water content in disc 
1) Acquired narrowing of lumbar spinal canal due to 
• Osteophytes 
• Sacralisation of L5 vertebrae 
• Ossified Posterior Longitudinal Ligament(OPLL) 
• Facet joint hypertrophy (results foraminal stenosis  &  compression of root of 
radicularartery) 
• Hypertrophied ligamentum flavum (Compress the cord during extension) 
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PATHOPHYSIOLOGY: 
The high incidence of simultaneous degenerative changes to the intervertebral 
disc, vertebral body, and associated joints suggests a progressive and dynamic 
mechanism, with interdependent changes occurring secondary to disc space 
narrowing. 
Intervertebral Joints: 
Adjoining vertebrae are connected to each other at three joints. There is a 
median joint between the vertebral bodies and two joints right and left between the 
articular processes.The joints between the articular processes are plane synovial 
joints.The joint between the vertebral bodies is a symphysis. The surfaces of the 
vertebral bodies are lined by thin layers of hyaline cartilage. Between these layers of 
hyaline cartilage there is a thick plate of fibrocartilage which is called the 
intervertebral disc. 
 
PATHOPHYSIOLOGY 
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Intervertebral Discs: 
These are fibro cartilaginous discs which intervene between the bodies 
ofadjacent vertebrae and bind them together. Their shape corresponds to that of the 
vertebral bodies between which they are placed. The thickness of the disc varies in 
different regions of the vertebral column, and in different parts of the same disc. In  
the cervical and lumbar regions the discs are thicker in front than behind, while in the 
thoracic region they are of uniform thickness. The discs are thinnest in the upper 
thoracic region and thickest in the lumbarregion. 
The discs contribute about one-fifth of the length of the vertebral column. The 
contribution is greater in the cervical and lumbar regions than in the thoracic region. 
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Each disc is made up of the following two parts: 
1. Nucleus Pulposus is the central part of the disc. It is soft and gelatinous at 
birth. It is kept under tension and acts as a hydraulic shock absorber. With 
advancing age the elasticity of the disc is muchreduced. 
2. Annulus Fibrosus forms the peripheral part of the disc. It is made up of a 
narrower outer zone of collagenous fibres and a wider inner zone of 
fibrocartilage. The fibres from laminae that are arranged in the form of 
incomplete rings. The rings are connected by strong fibrous bands. The outer 
collagenous fibres blend with the anterior and posterior longitudinal 
ligaments.Intervertebral discs are believed to undergo a “degenerative 
cascade” of three overlapping phases that may occur over the course of 
decades. 
Phase-I (Dysfunction Phase) 15 to 45 years describes the initial effects of 
repetitive microtrauma with the development of circumferential painful tears of the 
outer, innervated annulus, and associated end-plate separation that may compromise 
disk nutritional supply and waste removal. Such tears may coalesce to become radial 
tears, more prone to protrusion, and impact the disc‟s capacity to maintain water, 
resulting in desiccation and reduced disk height. Fissures may become ingrown by 
vascular tissue and nerve endings, increasing innervation and the disc‟s capacity for 
pain signal transmission. 
Phase-II (Instability Phase) 35 to 70 years is characterized by the loss of 
mechanical integrity, with progressive disc changes of resorption, internal disruption, 
and additional annular tears, combined with further facet degeneration that may 
induce subluxation andinstability. 
Phase-III (Stabilization Phase) 60 years and above is continued disc space 
narrowing and fibrosis occurs along with the formation of osteophytes and transdiscal 
bridging. 
There is a spectrum of pathological changes in facial joints and the disc and 
the interaction of these changes. Adjacent pedicles approximate with a narrowing of 
the superior-inferior dimension of the intervertebral canal. Laxity due to modest 
redundancy of the longitudinal ligaments enables bulging of the ligamentum flavum 
and potential for spine instability. Increased spine movement permits subluxation of 
the Superior Articular Process (SAP), causing a narrowed anteroposterior dimension 
of the intervertebral and upper nerve root canals. Laxity may also translate into altered 
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weight mechanisms and pressure relationships on vertebral bone and joint spaces 
believed to influence osteophyte formation and facet hypertrophy to both inferior and 
superior articular processes with risks for projection into the intervertebral canal and 
central canal, respectively. Oblique orientations of the articular processes may further 
cause retrospondylolisthesis, with resulting anterior encroachment of the spinal canal, 
nerve root canal, and intervertebralcanal. 
Biochemical research exploring osteophyte formation supports the above 
process. Osteophyte lipping is believed to form at periosteum through the 
proliferation of peripheral articular cartilage which subsequently undergoes 
endochondral calcification and ossification. Changing weight mechanics and pressure 
forces as well as alterations in oxygen tension and dynamic fluid pressure appear to be 
influential factors in osteophyte formation. Mesenchymal stem cells of the synovium 
or periostium are likely precursors, with synovial macrophages and a milieu of growth 
factors and extracellular matrix molecules acting as probable mediators in this 
process. 
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SYMPTOMS 
 
 
 
 
 
 
 
 
 
 
 
 
Loss of balance 
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SIGNS AND SYMPTOMS: 
When a patient suffers from lumbar spondylosis, it is possible that osteophytes 
are formed. These osteophytes are bony overgrowths that occur due to the stripping of 
the periost from the vertebral body. 
• Pain- can be produced when a neural foraminal stenosis is formed, which 
comes from the formation ofosteophytes. 
• Joint stiffness, which can limitmotion. 
• Neurologic claudication, whichincludes: 
• Lower backpain, 
• Legpain, 
• Numbness when standing andwalking. 
• Radiating pain towards the lowerextremities 
• Diffuse tenderness in lumbarbone 
• Exacerbation of painon movements 
• Pain increased on forward bending, sneezing,coughing 
• Paraesthesiaandsensorylossonaffectedarea 
• Burning and tingling sensation in lowerlimb 
• Painandstiffnessinlowback inthemorninghours 
Less Common Symptoms: 
• Loss ofbalance 
• Neurogenicbladder. 
EXAMINATION: 
When a physician performs an examination for lumbar spondylosis, it is 
advised to follow the principles of the general spine examination and apply them to 
this specific pathology. General examination of the spine: 
• The examination should begin with careful observation during the whole 
consultation. 
• It is essential to observe the patient's gait andposture. 
35 
 
EXAMINATION OF LUMBAR SPINE 
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1)Inspection: 
• Inspection of the entirespine. 
• Look for any obvious swellings or surgicalscars. 
• Assess for deformity: scoliosis, kyphosis, loss of lumbar lordosis or 
hyperlordosis of the lumbar spine. Look for shoulder asymmetry and pelvic 
tilt. 
2)Palpation: 
• Palpate for tenderness over bone and softtissues. 
• Perform an abdominal examination to identify any masses and consider a 
rectal examination to exclude other pathologies in thisregion 
Inference: 
• No tenderness to palpation is noted, but some discomfort can be elicited with 
deep percussion over the midline of the lumbararea. 
• Physical findings that may also be present include antalgic or normal gait, 
tight lumbar musculature and hamstrings, hyperlordosis, and buttock or thigh 
pain. 
1)Movement: 
• Examination of the spine must also include examination of the shoulders and 
examination of the hips to exclude these joints as a cause of thesymptoms. 
To test flexion: 
• Instruct the patient to bend forwards as much as possible at the waist. 
• Normal flexion is 80o or finger tips 3-4 inches from the floor. 
Lateral Flexion: 
• Instruct the patient to bend to the leftand to the right as far as possible. 
• Normal range is 35o on each side. 
Extension: 
• Instructs the patient to bend at waist as far backward as possible. 
• Normal range is20o-30o. 
Rotation: 
• Instructs the patient to rotate from the waist to the left and to the right as far as 
possible. Normal range is 45oC possible 
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FEMORAL NERVE STRETCH TEST 
 
 
SCHOBER’S TEST 
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1. Neuro vascular examination: 
• A thorough examination of sensation, tone, power and reflexes should be 
performed. 
• Always consider the possibility of acute spinal cord compression, which is a 
neurosurgicalemergency. 
• All peripheral pulses should also be checked, as vascular claudication in the 
upper and lower limbs can mimic symptoms of radiculopathy or canalstenosis 
2. Tests for Examination: 
• Straight Leg Raising test(SLR) 
• Braggards test 
• Femoral nerve stretch test 
• Schobers test 
• Forward bending to touch the toes 
• Flip test 
• Lassegue test 
• Bowstring sign 
OUTCOME MEASURES: 
Numeric Pain Rating Scale (NPRS): The patient is asked to score 3 pain 
rating, worse / current / best over the last 24 hour. The score for this scale is the 
average of these 3 values. This scale is a variant of the VAS but also assess pain 
intensity. 
Roland Morris Disability Questionnaire (RMDQ): This questionnaire contains 
sentences that people have used to describe themselves when they have back pain on 
that specific day. As people read the list they might recognize themselves and then 
they must tick that box. A score is appointed according to the amount of boxes the 
patient fills in. This questionnaire makes it possible to follow changes in time. 
Oswestry Disability Index (ODI): This index is made to evaluate how back 
pain invalidates people in their daily activities (sleeping, self-care, sex life, social life 
and travelling). Each question contains 6 categories (0: no limitation 6: most 
limitation). The score is calculated by the sum of the 10 questions, multiplied by 2. 
This value represents the percentage of invalidation. 
Pain Self-Efficacy Questionnaire (PSEQ): This questionnaire rates how 
confident patients feel performing activities despite the pain. This is indicated on a 
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scale from 0 (no confidence) to 6 (completely confident). Al the scores are then added 
up to a score from 0 to 60. Where the closer to 60 means that the patients have a 
stronger self-efficacy belief. There are also short versions of this questionnaire 
available who shows also a great responsiveness. 
Patient-Specific Functional Scale: Questionnaire where patients are asked to 
identify up to three activities that they had difficulty with or are unable to perform as 
a result of their back pain. Each item is given a score of 0-10 (unable- able). The total 
score is assessed by the sum of the activity scores/number of activities (Minimum 
detectable change (90%CI) for average score = 2 points, Minimum detectable change 
(90%CI) for single activity score = 3 points) of all those questionnaires the NRPS is 
recommended for assessing pain because of this ease of administration and 
responsiveness. The ODI and RMDQ are recommended for assessingfunctioning. 
DIAGNOSIS: 
For the clinical diagnosis of lumbar spondylosis, a thorough investigation is 
necessary to ensure that other pathologies are excluded. 
 MRI: Shows the greatest details in the spine and is used to visualize the 
intervertebral discs, including the degree of disc herniation, if present. An 
MRI is also used to visualize the vertebrae, the facet joints, the nerves, and the 
ligaments in the spine and can reliably diagnose a pinchednerve. 
 X-Rays: show bone spurs on vertebral bodies in the spine, thickening of facet 
joints (the joints that connect the vertebrae to each other), and narrowing of 
the intervertebral discspaces. 
 CT scan: able to visualize the spine in greater detail and can diagnose 
narrowing of the spinal canal (spinal stenosis) whenpresent. 
 SPECT: Single-photon emission computedtomography. 
 Bone scintigraphy is used to further evaluate patients with suspected 
spondylosis. Controversy surrounds the designation of one of these tests as 
most useful in the evaluation ofspondylosis. 
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RADIOLOGICAL FINDINGS 
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Myelogram: 
Helping in detecting: 
 Intra spinallesion 
 Spinalstenosis 
 Any compression of the spinalcord 
 Discography 
 Nerve conduction studies 
 EMG 
These procedures were validated in several studies, which concluded that MRI 
was effective (92% sensitivity) in identifying pars lesions. CT scan was also used as a 
diagnostic procedure, but the result weren‟t equally positive. That is the reason why 
MRI is advised as the best method of diagnosis. 
DIFFERENTIAL DIAGNOSIS: 
1. Osteoporosis 
2. Multiple myeloma 
3. Multiple sclerosis 
4. Extra dural tumor 
5. Ankylosis spondylosis 
6. Spino vascular insufficiency 
7. Peripheral neuropathy 
8. Herpes zoster 
9. TB Spine 
10. Rheumatoid arthiritis 
11. SLE 
12. Mixed connective tissue disorder 
COMPLICATIONS: 
• Nerve compression from posterior osteophytes is a possible  complication only 
if a neuroforamen is reduced to less than 30% of normal. 
• If lumbar spondylosis projects into the spinal canal, spinal stenosis is a 
possible complication 
• An isolated report of a bony L4 mass pressing on the duodenum has been 
described. 
• Cauda equina syndrome 
• Neurogenic claudication 
• Paraplegia 
• Conus Medullaris Syndrome 
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CHAPTER-IV 
MATERIALS AND METHODS 
 A Prospective open labelled non randomised Phase-II Clinical trial to assess 
the therapeutic efficacy of the siddha formulation Munnai Ilai  Kudineer for the 
treatment of THANDAGA VATHAM (Lumbar Spondylosis) is carried out in Post 
Graduate Department of Pothu Maruthuvam, Government Siddha Medical College 
and Hospital, Palayamkottai. 
Selection of the Cases: 
Totally 40 cases were selected. Out of 40, 20 cases were selected as Inpatients 
and 20 cases treated as Out patients. These cases were selected from the Out patient 
Department of Pothu Maruthuvam according to the inclusion and exclusion criteria. 
Aetiological factors: 
The seasonal variations and precipitating factors like emotional stress and 
strain, trauma, occupation and food habits were enquired and recorded. The socio 
economic status, family history and other significant diseases treated already, were 
thoroughly registered. 
1. INCLUSION CRITERIA  
Patients having textual symptoms of Lumbar Spondylosis will be taken as a 
subject to the study  
• Patients of either sex were included in the study  
• Patients of age group between 30-60 yrs. 
• Patients with low back pain with radiograph of lumbosacral spine showing,  
• Loss of natural lumbar lordosis 
• Reduction in disc space  
• Formation of osteophytes  
• Osteoporosis  
• Subluxation of one vertebra over another.  
2. EXCLUSION CRITERIA 
• Age below 30 years and above 60 years. 
• Diabetes mellitus 
• Auto immune diseases like SLE 
• Chronic Kidney Disease 
• Fracture of Spine 
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• Tuberculosis of Spine 
• Congenital spino vertebral deformities 
• Cardiac disease. 
3. WITHDRAWAL CRITERIA 
The patients were withdrawn from the trial if,  
• Occurrence of adverse effects with given treatment, also if patient needs 
emergency management. 
• The investigator feels that the protocol has been violated. 
• Further continuation of the study is likely to be detrimental to health of the 
patients  
• The patient is not willing to continue the trial 
Diagnosis: 
The diagnosis is made by following Siddha diagnosis methods: 
• Poriyalaridhal 
• Pulanalaridhal 
• Vinadhal 
• Envagai thervugal 
• Udal thathukkal 
• Kaalam 
• Nilam 
Haematological Investigations: 
• HB% 
• Total WBCCount 
• DifferentialCount 
• Erythrocyte SedimentationRate 
• Blood SugarR/PP/F 
• BloodUrea 
• SerumCholesterol 
• SerumCreatinine 
• Serum UricAcid 
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Urine analysis: 
• Albumin 
• Sugar 
• Deposits 
Specific Investigations: 
• RAfactor 
• ASOtitre 
• CRP 
Radiological Investigations: 
• X-Ray of Lumbar Spine (AP and lateralview) 
Assessment of result: 
The results were assessed on the basis of symptomatic relief, improvement in 
grade of cardinal signs and range of movements and by back pain functional 
assessment scale. 
The difference in the grade and score before and after treatment represents the 
improvement in the treatment. 
Further the biochemical, pharmacological and acute toxicity studies were done 
in Government Siddha Medical College, Palayamkottai and KM Pharma College 
Madurai. 
Treatment: 
The clinical trial drug “MUNNAI ILAI KUDINEER”30ml twice a day after 
food is given for 30 days till the end of the course.All the patients admitted for the 
study were given uniformly regular hospitaldiet.After discharge all the patients were 
advised to attend the Out patient Department of Pothu Maruthuvam, Government 
Siddha Medical College and Hospital, Palayamkottai for further followup. 
Ethical Review 
The study was conducted in accordance with the ethical principles that are 
consistent with good clinical practice guidelines and obtained prior approvals before 
start of the teial from the Institunal Ehical Committee of GSMCH 
,palayamkottai(GSMC-IV-IEC/2017/Br-I/07/29.05.2017) and Instiuional animal 
ethical committee (IEAC) of K.M College of pharmacy, Madurai 
(TNMGRMU/KMCP/IEAC/20/2018). The trial was applied and approved by the 
Clinical Trial Registry of India.  
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CHAPTER-V 
OBSERVATION AND RESULT 
5.1 PRE CLINICAL STUDY 
 5.1.1ANALGESIC ACTIVIY 
Evaluation of Analgesic Activity of Siddha formulation Munnai Ilai Kudineerin 
Animal Models 
Introduction 
Inflammation and pain are common nonspecific manifestations of many 
diseases. Although non-steroidal anti-inflammatory drugs (NSAIDs) and opiates have 
been used classically in these conditions, but some adverse reactions occur with these 
drugs such as gastrointestinal disturbances, renal damage, respiratory depression, and 
possible dependence (1-2). In recent years, there has been an increasing interest to 
find new anti-inflammatory and analgesic drugs with possibly fewer side effects from 
natural sources and siddha formulations. 
Based on Indian folk medicine, in the present study analgesic effects were 
evaluated for siddha formulation Munnai Ilai Kudineer in mice using acetic-acid 
writhing test.. 
Animals 
24 adult male albino mice (25-35 g) were housed in animal 
house,K.M.College of Pharmacy,Madurai,under standard laboratory conditions 
(temperature 23 ± 2 ˚C) with 12 h dark and 12 h light cycle. The animals had free 
access to standard dry pellet diet and tap water ad libitum 
Analgesic activity 
Acetic acid-induced writhing test 
The acetic-acid writhing test was performed using the reported procedure (3) 
Groups of rats (n=6), were administered with100 and 200 mg/Kg of siddha 
formulation Munnai Ilai Kudineer,10 mg/Kg Diclofenac as positive control group and 
1 mL distilled water as negative control group. After 30 minutes the animals were 
administered with i.p. injection of 0.1 mL acetic acid (0.6%). Then the count of 
abdominal contractions of animals during 30 minutes after acetic acid injection was 
reported and the Percentage Analgesic Activity (PAA) was calculated by using the 
following formula: 
PAA = ((C- CD)/CD) ×100 
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C = Mean of contractions’ count in animals treated with different doses of 
siddha formulation Munnai Ilai Kudineer and Diclofenac sodium  
CD = Mean of contractions’ count in animals served as negative control 
Statistical analysis 
The results are reported as mean ± S.E.M. The statistical analyses were 
performed using one way analysis of variance (ANOVA). Group differences were 
calculated by post hoc analysis using Tukey’s test. For all tests, differences with 
values of P<0.05 were considered significant. 
Results 
Acetic acid-induced writhing response 
The second study showed that the application of different doses of siddha 
formulation Munnai Ilai Kudineer had significant analgesic effects in the animals 
under investigation. The results of doses 100 and 200 mg/Kg were significant and 
comparable with the effect of Diclofenac sodium in analgesic activity (Table 1). 
Table 5.1.2.a. Effects of siddha formulation Munnai Ilai Kudineeron acetic acid–
induced writhing response (N=6 in each group). 
Groups Treatment 
(number of 
writhing 
movements) 
(Mean ± S.E) 
Percentage % 
Group I Distilled water 30.00 ± 2.52  
Group II Diclofenac sodium 
10mg/kg 
6.30 ± 0.98*b 
 
79.00% 
Group III 100mg/kg  
Munnai Ilai Kudineer 
15.45 ± 1.72*b 48.50% 
Group IV 200mg/kg 
 Munnai Ilai Kudineer 
13.40 ± 1.32*b 55.33% 
• Values are expressed as mean ± SEM. 
* (b) Values are significantly different from Toxic  control G2 at  P<0.01. 
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Discussion and conclusion 
The analgesic activity was assessed by writhing test which has been reported 
to be useful for investigation of peripheral antinociceptive activity and performed as a 
chemical pain model (4,5). The siddha formulation Munnai Ilai 
Kudineerdemonstrated a dose-dependent, significant antinociceptive activity in 
animal models of pain. Acetic acid believed to increase the PGE2 and PGF2α in 
peritoneal fluid (6). The analgesic activity shown in models of pain is indicative that 
siddha formulation Munnai Ilai Kudineer might possess centrally and peripherally 
mediated antinociceptive properties.  
Chemical components of siddha formulation Munnai Ilai Kudineer such as 
flavonoids, saponins or phenolic compounds may be responsible for the 
antinociceptive activities of this formulation. Since the findings of this study revealed 
a significant analgesic effect of the siddha formulation Munnai Ilai Kudineer, it can be 
concluded that terpenoids and specially saponins of siddha formulation Munnai Ilai 
Kudineermay be responsible for the observed analgesic effect which should be proved 
by further investigations.  
It can be concluded that possesses anti-nociceptive properties which are 
probably mediated via inhibition of prostaglandin synthesis as well as central 
inhibitory mechanisms which may be of potential benefit for the management of pain 
and inflammatory disorders. 
5.1.2   ANTI-INFLAMMATORY ACTIVITY 
EVALUATION OF CARRAGEENAN INDUCED ANTI-INFLAMMATORY 
ACTIVITY OF SIDDHA FORMULATION MUNNAI ILAI KUDINEERIN  
ALBINO WISTAR RATS 
Introduction 
Inflammation is a complex biological response of vasculartissues against 
aggressive agents such as pathogens, irritants,or damaged cells. Acute inflammation is 
the initial responseand is characterized by the increased movement of plasmaand 
innate immune system cells, such as neutrophils andmacrophages, from the blood into 
the injured tissues. The stan-dard signs of inflammation are expressed by increased 
bloodflow, elevated cellular metabolism, vasodilatation, release ofsoluble mediators, 
extravasation of fluids and cellular influx. Upon the presence of the inflammatory 
agent, cell mem-branes induce the activation of phospholipase A2 followed byrelease 
of arachidonic acid and inflammatory mediators such ascytokines, serotonin, 
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histamine, prostaglandin and leukotrienesthat increase vascular permeability, thus 
facilitating the migra-tion of leukocytes to the site of inflammation. 
Inflammationinduced by carrageenan is acute, nonimmune, well-researched,and 
highly reproducible. Cardinal signs of inflammation—edema,hyperalgesia, and 
erythema—develop immediately following sub-E-mail address: 
sumana.sarkhel@yahoo.incutaneous injection, resulting from action of 
proinflammatoryagents—bradykinin, histamine, tachykinins, complement and reac-
tive oxygen, and nitrogen species.Many saponins tested have displayed significant 
antinocicep-tive, anti-inflammatory and antipyretic activities possibly due totheir 
nonglycosidic moiety, the sapogenin, but also many diverseactivities have also been 
reported such as antiallergic, antifungal,analgesic and others . Moreover a variety of 
siddha formulation preparation haveproved to be useful in animal models of 
inflammation [7–10]. 
Paw swelling, or footpad edema, is a convenient method for assessing 
inflammatory responses to antigenic challenges and irritants. Typically, test 
compounds are assessed for acute anti-inflammatory activity by examining their 
ability to reduce or prevent the development of carrageenan-induced paw swelling. In 
the present study attempts are made to validate the claims of Munnai Ilai Kudineer 
regarding the anti-inflammatory activities of this siddha preparation. 
Methods & materials 
Animals  
Male albino rats (180 ± 5 g) were obtained from animal house,K.M.College of 
pharmacy,maduarai and maintained in standard laboratory conditions. They were 
given standard labora-tory diet and water ad libitum. All animal experiments are 
approved by the Institutional Animal Ethics Committee, and were in accordance with 
the guidelines of the committee for the purpose of Control and Supervision of Experi-
ments on Animal (CPCSEA), Government of India. 
Acute inflammation  
Carrageenan-induced rat paw oedema is used widely as a work-ing model of 
inflammation in the search for new anti-inflammatory drug. The anti inflammatory 
activity of the siddha formulation Munnai Ilai Kudineer was evaluated by 
carrageenan-induced rat paw oedema method [11]. Albino Wistar rats (180 ± 5 g) 
were used. Antiinflammatory activity was measured using carrageenan induced rat 
paw oedema assay. The rats were divided into 5 groups of 5 animals each. Group 
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I.were given normal saline and treated as negative control. Rats of Group II was 
treated with carragenan (1%w/v) in saline in the subplanter region of the right hind 
paw Rats in Group III were administered Indomethacin(10 mg/kg, bw) and considered 
as standard. Rats from Group IV and V were given two doses siddha formulation(100 
and 200 mg/kg bw). Acute paw edema was induced by injecting 0.1 ml of 1% (w/v) 
carrageenan solution, pre-pared in normal saline. After 1 h, 0.1 ml, 1% carrageenan 
suspension in 0.9% NaCl solution was injected into the sub-plantar tissue of the right 
hind paw. The linear paw circumference will be measured at hourly interval for 4 h. 
The perimeter of paw was measured by using vernier callipers. Measurements were 
taken at 0–4 h after the administration of the carrageenan.  
The anti-inflammatory activity was calculated by using the rela-tion  
%inhibition of edema =   T − T0 
    _____________ X 100 
     T 
T, Thickness of paw in control group; T0, Thickness of paw edema in the test 
compound treated group. 
Carrageenan Induced Pleurisy In Rats 
The animals were divided into five groups of five rats each as described in the 
carrageenan induced pawedema model [12,13] and each were pretreated with siddha 
formulation(100 and 200 mg/kg, p.o.), Indomethacin(10 mg/kg, p.o.) or normal saline 
(0.1 ml).One hour later all the animals were received 0.25 ml ofan intrapleural 
injection of 1 % carrageenan on the rightside of the thorax. The animals were 
sacrificed 3 h aftercarrageenan injection by ether inhalation. One ml ofheparinized 
Hank’s solution was injected into the pleuralcavity and gently massaged to mix its 
contents. Thefluid was aspirated out of the cavity and the exudateswere collected. The 
number of migrating leukocytes inthe exudates was determined with Neubauer 
chamber. 
The values of each experimental group were expressedas mean ± SEM and 
compared with the control group. 
Statistical analysis 
  Results of antiinflammatory activity were expressed as Mean increase in paw 
diameter ± SD. Results were analyzed using one way ANOVA. Differences were 
considered as statistically significant at P < 0.05 are compared to control. 
 
50 
 
Table 5.1.2(a) Effect of siddha formulation Munnai Ilai Kudineer on Carrageenan 
Induced Rat Paw Edema. 
Treatment 
 
Dose 
(mg/kg, p.o.) 
 
Mean increase 
in paw volume 
(ml) 
% Decrease 
in paw 
volume 
Normal control 10ml/kg saline 1.05 ± 0.09  
Toxic control 0.1 ml, 1% carrageenan 3.45 ± 0.24*a 
 
 
Standard control 10mg/kg Indomethacin 1.20 ± 0.12*b 
 
65.21% 
Treatment control 100mg/kg Munnai Ilai 
Kudineer 
1.40 ± 0.18*b 
 
59.42% 
Treatment control 200mg/kg Munnai Ilai 
Kudineer 
1.32 ± 0.14*b 
 
61.73% 
* (a) Values are significantly different from normal control G1 at P<0.01. 
* (b) Values are significantly different from Toxic  control G2 at  P<0.01. 
Table 5.1.2.b.Effect of siddha formulation Munnai Ilai Kudineeron Carrageenan 
Induced Pleurisy in Rats. 
Treatment 
Dose 
(mg/kg, p.o.) 
Pleural exudates 
(ml) 
Leukocytes 
(×103 cells/ml) 
Normal control 10ml/kg saline 0.14±0.05 0.37±0.03 
Toxic control 0.1 ml, 1% 
carrageenan 
0.42±0.14*a 4.20±0.36*a 
Standard control 10mg/kg 
Indomethacin 
0.15±0.06*b 0.46±0.05*b 
Treatment control 100mg/kg Munnai 
Ilai Kudineer 
0.21±0.09*b 0.54±0.08*b 
Treatment control 200mg/kg Munnai 
Ilai Kudineer 
0.16±0.07*b 0.51±0.06*b 
(a) Values are significantly different from normal control G1 at P<0.01  
(b) Values are significantly different from Toxic control G2 at  P<0.01. 
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Anti-inflammatory Activity of siddha formulation Munnai Ilai Kudineer 
The above Table no 5.2 (a) showed the effect of siddha formulation Munnai 
Ilai Kudineeron carrageenan-induced edema in rats. Theresults obtained indicate that 
the siddha formulation Munnai Ilai Kudineer hadsignificant anti-inflammatory 
activity in rats. The siddha formulation Munnai Ilai Kudineer reduced the edema 
induced bycarrageenan by 59.42% and 61.73% on oral administration of 100 and 200 
mg/kg, as compared to the untreated control group. 
Indomethacinat 10 mg/kg inhibited the edema volume by 65.21%. 
The  aboveTable 5.2 (b) the effect of siddha formulation Munnai Ilai 
Kudineeron carrageenan-induced pleurisy in rats were ( 0.42±0.14 ml treated with the 
siddha formulation Munnai Ilai Kudineer(100 and 200 mg/kg, p.o.) decreased the 
pleuralexudates to 0.21±0.09 ml and 0.16±0.07.Treatment with Indomethacin(10 
mg/kg, p.o.)produced the exudates of0.15±0.06 ml. The leukocyte count for the 
controlgroup was found to be 4.20±0.36×103 cells/ml. Animalstreated with the siddha 
formulation Munnai Ilai Kudineer and standard produced aleukocyte migration of 
0.54±0.08×103,0.51±0.06X103 and 0.46±0.05×103 cells/ml, respectively. 
DISCUSSION 
Due to the increasing frequency of intake of NSAID’s and their reported 
common side effects, thereis need to focus on the scientific exploration of siddha 
formulation drugs having fewer side effects. So, there is a continuoussearch for 
indigenous drugs, which can provide relief to inflammation. Carrageenan induced 
inflammation is a biphasicphenomenon. The first phase of edema is attributed to 
release of histamine and 5-hydroxytryptamine. Plateauphase is maintained by kinin 
like substances andsecond accelerating phase of swelling is attributed toprostaglandin 
like substances. The knowledge of thesemediators involved in different phases is 
important forinterpreting mode of drug action.The tests performed with the siddha 
formulation Munnai Ilai Kudineer in the pleurisy model showed that the siddha 
formulation Munnai Ilai Kudineer behaves as an inhibitor of leukocyte migration and 
theformation of pleural exudates when given orally, as reportedearlier. 
Thus it can be concluded that the siddha formulation Munnai Ilai Kudineer 
possess significant anti-inflammatory activityin rats. Further studies involving the 
purification of the prerpation and the investigationsin the biochemical pathways may 
result in the developmentof a potent anti-inflammatory agent with a low ( Table 
5.2.a&b). 
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5.1.3.TOXICITY STUDY 
Acute toxicity study of Munnai ilai kudineer 
Cage Side Observations 
 Observations include changes in skin and fur, eyes and mucous membranes, 
and also respiratory, circulatory, autonomic and central nervous systems, and 
somatomotor activity and behavior pattern. Special attention is directed for the 
observation of tremors, convulsions, salivation, diarrhea, lethargy, sleep and 
coma.Body Weight, Food and Water Intake.Body weight, food and water intake are 
recorded at two-day intervals.  
Pathology 
 Surviving animals are fasted overnight, weighed and humanely killed on the 
15th day using anesthetic ether. All test animals are subjected to gross necropsy. 
Subchronic test for Munnai ilai kudineer 
This experiment evaluates the toxicity potential ofMunnai ilai kudineer. 
Method:  
Male and female Wistar rats weighing 180 ± 10 g are used for the present 
study. The animals are divided into five groups of six animals each. The dose of the 
preparation is calculated based on the body weight of the animal.   The animals in 
Group I are administered with a single daily dose of 0.5 ml of Tween 80 orally for 20 
days. The animals in Group II are administered with 50 mg.kg-1 b.w. of the Munnai 
ilai Kudineer orally once daily for 20 days. The animals in Group III are administered 
with 100 mg.kg-1 b.w. of the Munnai ilai kudineerorally once daily for 20 days. The 
animals in Group IV and V are administered once daily with 200 and 400 mg.kg-1 
b.w. of the Munnai ilai Kudineer respectively for 20 days orally (Pieme,et al 2006, 
Joshi, et al 2007, Mythilypriya, et al., 2007)The animals are then weighed every five 
days, from the start of the treatment, to record the weight variation. At the end of the 
treatment, blood samples are collected by puncturing retro orbital plexus after mild 
anesthesia for biochemical analysis. The collected blood sample is centrifuged within 
5 min of collection at 4000 g for 10 min to obtain plasma, which is analyzed for total 
cholesterol, total triglyceride, HDL-cholesterol levels, LDL-cholesterol, plasma 
glucose, alanine aminotransferase (ALT), aspartate aminotransferase (AST), 
creatinine and urea. 
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Results 
Acute toxicity study with Munnai ilai kudineer 
 The acute toxicity of Munnai ilai kudineerwas evaluated usingOECD- 423 
guidelines. There was no mortality or morbidity observed in animals through the 15-
days period following single oral administration at all selected dose levels of the 
Munnai ilai kudineer(Table-5.3.a).   The animals did not show any changes in the 
general appearance during the observation period. Morphological characteristics such 
as fur, skin, eyes and nose appeared normal. No tremors, convulsion, salivation, 
diarrhea, lethargy or unusual behaviors such as self mutilation, walking backward and 
so forth were observed.  Gait and posture, reactivity to handling or sensory stimuli, 
grip strength was also normal.  
Table.5.1.3.a Acute toxicity studyof Munnai ilai kudineeron experimental mice. 
 Dose (mg.kg-1) Sign of Toxicity 
(ST.NB-1) 
Mortality (D.S-1) 
Group I              0                      0/3            0/3 
Group II            300                      0/3            0/3 
Group III           2000                      0/3            3/3 
 
The acute toxicityof Munnai ilai kudineeron experimental mice was tested 
using OECD-423 guidelines, where ST- sign of toxicity; NB- normal behaviour; D- 
died; S- survive.  Values are expressed as number of animals (n=3). 
Effect of Munnai ilai kudineer in Subchronic Toxicity  
Munnai ilai kudineerwere evaluated for subchronic toxicity. 
Effect of Munnai ilai kudineeron body weight changes in rats 
 The effect of Munnai ilai Kudineer was observed for their effect on the body 
weight changes from the study it was observed that, there was significant increase 
(p<0.05) in body weight in all the animals observed.    
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Table5.1.3.bThe effects of Munnai ilai kudineer on body weight changes in rats. 
Treatment Day 1 Day 5 Day 10 Day 20 
Control 186.15±6.8 188.45  ±6.20 193.15 ±6.35 197.7±6.58 
Munnai ilai kudineer 
 50 mg.kg-1 
193.30 ±6.4 194.30  ±6.30 195.25 ±6.70 199.30±6.72* 
Munnai ilai kudineer 
100 mg.kg-1 
185.35 ±5.7 190.30  ±6.40 198.55  ±7.10 198.36±6.30* 
Munnai ilai kudineer 
200 mg.kg-1 
194.30  ±7.2 199.15±6.50 195.90  ±7.20** 207.45±7.26** 
Munnai ilai kudineer 
400 mg.kg-1 
190.65  ±6.05 193.15 ±5.60 192.60  ±6.35** 208.66±7.38** 
 
A study on the effects of Munnai ilai kudineeron body weight changes in rats 
was carried out.. where, group I animals (GPI) were treated with normal saline (5 
ml.kg-1), group II animals (GPII) with 50 mg.kg-1 of Munnai ilai kudineer,  group III 
animals (GPIII)  with 100 mg.kg-1 of Munnai ilai kudineer, group IV animals (GPIV)  
with 200 mg.kg-1 of Munnai ilai kudineer,group V animals (GPV)  with 400 mg.kg-
1Munnai ilai kudineer. According to Table no 5.1.3 a&b the values are expressed as 
mean ± S.E.M. n=6. The results of group I were compared with other groups such as 
II, III, IV, and V.   The statistical analysis was carried out using one way ANOVA 
method, where **P<0.01 *P<0.05. 
Effect of Munnai ilai kudineeron kidney,heart, liver and brain in rats  
The table no 5.3c expressed  the effects of Munnai ilai kudineeron kidney, 
heart, liver and brainof the rats were observed.From the study it was clear that, 
significant (p<0.01) changes in the weights of various organs of the animals occurred 
with higher doses of the extract (400 mg.kg-1 bwt), but macroscopic examinations did 
not show any changes in colour of the organs of the treated animals compared with 
the control. 
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Table.5.1.3.c The results are shown in Internal organs: 
Treatment Heart (gms) Kidney (gms) Liver (gms) Brain (gms) 
Control 0.37 ± 0.05 0.66± 0.03 3.31± 0.05 0.64± 0.05 
Munnai ilai kudineer 
@50 mg.kg-1 
0.38± 0.02 0.82± 0.03 3.41± 0.03 0.67± 0.3 
Munnai ilai kudineer 
@100 mg.kg-1 
0.39± 0.06 0.80± 0.04 3.33±0.02 0.65± 0.2 
Munnai ilai kudineer 
@ 200 mg.kg-1 
0.38± 0.04 0.75± 0.02 3.31± 0.02 0.72± 0.05 
Munnai ilai kudineer 
@400 mg.kg-1 
0.37± 0.03 0.76± 0.03 3.34± 0.03 0.76± 0.05 
 
Table.5.1.3.cThe effects of Munnai ilai kudineer on kidney, heart, liver and 
brain of the rats. A study on the effects of Munnai ilai kudineer on kidney, heart, 
liver and brainof the rats was tested. where, group I animals (GPI) treated with normal 
saline (5 ml.kg-1), group II animals (GPII)  with 50 mg.kg-1 of Munnai ilai kudineer,  
group III animals (GPIII)   with 100 mg.kg-1 of Munnai ilai kudineer, group IV 
animals (GPIV)   with 200 mg.kg-1 of Munnai ilai kudineer, group V animals (GPV)  
with 400 mg.kg-1Munnai ilai kudineer.  The values are expressed as mean ± S.E.M. 
n=6.   The results of group I were compared with other groups such as II, III, IV,  and 
V.  The statistical analysis was carried out using one way ANOVA method, where 
**P<0.01. 
Effect of Munnai ilai kudineeron biochemical profiles of rats   
The effect of Munnai ilai kudineer on various biochemical parameters of the 
experimental animal ‘rats’ were tested.From the study it was evident that, there was 
significant decrease (p<0.05) in the plasma glucose level in treated rats especially at 
higher dose (400 mg.kg-1) compared with control rats.   The control rats were 
administered only with 5 ml of normal saline.   Significant decrease (p<0.05) in the 
plasma total cholesterol (TC), triglyceride (TG) and LDL-cholesterol levels were 
observed.   But a significant increase (p<0.05) in HDL-cholesterol levels were 
observed in all the treated animals compared with the control animals. AST, ALT and 
ALP levels were also normal in the Munnai ilai kudineertreated animals. From the 
results of biochemical study there was no evidence of severe toxicity associated with 
the administration of higher concentration of Munnai ilai kudineer.  
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Table.5.1.3.e.The  Biochemical results 
Treatment 
Glucose 
(mg.dl-1) 
Cholesterol 
(mg.dl-1) 
Triglyceride 
(mg.dl-1) 
HDL 
(mg.dl-1) 
LDL 
(mg.dl-1) 
Control 96.65± 0.62 39.62± 0.56 28.25± 0.45 138.25± 0.55 87.15±1.72 
Munnai ilai 
kudineer@ 50 
mg.kg-1 
94.50± 0.56 27.85± 0.25* 13.22± 0.23* 178.28± 
0.65* 
74.59±1.28 
Munnai ilai 
kudineer@ 
100 mg.kg-1 
91.45± 0.47 28.74± 0.26* 15.42± 0.28* 168.18±0.78* 71.84±1.10 
Munnai ilai 
kudineer@ 
200 mg.kg-1 
92.25± 
0.55** 
35.18± 0.30 17.84± 0.38* 187.30± 
0.84* 
50.60±1.30 
Munnai ilai 
kudineer@ 
400 mg.kg-1 
88.25± 
0.45** 
34.78± 0.28 19.28± 0.34* 185.2± 0.85* 49.50±0.84 
 
 
According to Table.5.1.3.ethe effect of Munnai ilai kudineeron biochemical 
parameters such as glucose, cholesterol, triglyceride, HDL and LDL. A study on the  
effect of Munnai ilai kudineeron biochemical parameters such as glucose, cholesterol, 
triglyceride, HDL and LDL in rats was tested.where, group I animals (GPI) treated 
with normal saline (5 ml.kg-1), group II animals (GPII)  with 50 mg.kg-1 of Munnai 
ilai kudineer,  group III animals (GPIII)  with 100 mg.kg-1 of Munnai ilai kudineer, 
group IV animals (GPIV)  with 200 mg.kg-1 of, group V animals (GPV)   with 400 
mg.kg-1Munnai ilai kudineer. The values are expressed as mean ± S.E.M. n=6.   The 
results of group I were compared with other groups such as II, III, IV, and V.  The 
statistical analysis was carried out using one way ANOVA method, where **P<0.01 
*P<0.05 
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Table.5.1.3.f The effects of Munnai ilai kudineeron biochemical parameters such as 
AST, ALT, ALP, TP and Albumin in rats. A study on the effects of Munnai ilai 
kudineeron biochemical parameters. 
Treatment 
AST 
(IU.l-1) 
ALT 
(IU.l-1) 
ALP 
(IU.l-1) 
TP 
(g.l-1) 
ALBUMIN 
(g.l-1) 
Control 320.5±12.40 75.5± 3.18 256.58± 
8.80 
74.85± 3.32 39.15±2.35 
Munnai ilai 
kudineer@5
0 mg.kg-1 
309.0±9.50** 73.5± 2.20** 269.10± 
2.75** 
74.30± 2.32 36.30±2.65 
Munnai ilai 
kudineer@ 
100 mg.kg-1 
310.3±7.20** 71.1± 3.15** 263.18± 
6.70** 
84.15± 2.82 38.30±3.05 
Munnai ilai 
kudineer@ 
200 mg.kg-1 
305.4±7.95 66.4± 2.90 268.00± 
5.20 
69.25± 3.32 40.20±2.75 
Munnai ilai 
kudineer@ 
400 mg.kg-1 
315.2± 8.20 68.3± 3.52 272.40± 
4.40 
76.05± 2.58 39.48±2.70 
 
The effects of Munnai ilai kudineer on biochemical parameters such as AST, 
ALT, ALP, TP and Albumin in rats. A study on the effects of Munnai ilai kudineer 
on biochemical parameters such as AST, ALT, ALP, TP and Albumin rats was tested. 
where, group I animals (GPI)  were treated with normal saline (5ml.kg-1),  group II 
animals (GPII) with 50 mg.kg-1 of HAEBD group III animals (GPIII)  with 100 
mg.kg-1 of Munnai ilai kudineer, group IV animals (GPIV)  with 200 mg.kg-1 of 
Munnai ilai kudineer,  and group V animals (GPV)  with 400 mg.kg-1Munnai ilai 
kudineer The values are expressed as mean ± S.E.M. n=6.   The results of group I 
were compared with other groups such as II, III, IV, and V.   The statistical analysis 
was carried out using one way ANOVA method, where **P<0.01 *P<0.05 (Table 
no5.1.3 f) 
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Effect of Munnai ilai kudineeron haematological parameters in rats   
The effects of Munnai ilai kudineerwere observed for its effect on 
haematological parameterson the experimental rats. From the study it was evident 
that, a significant increase (p<0.01) were observed in the haemoglobin contents and  
RBC count  in the group treated with 200 mg.kg-1 body weight of Munnai ilai 
kudineerand a significant decrease of the parameters occurred in the group treated 
with 400 mg.kg-1 b.w.t compared with the control.   There was no significant change 
in the calcium level in all the treated animals compared to the control. 
Table.5.1.3.g.The effect of Munnai ilai kudineer on haematological parameters such 
as HB, Calcium, RBC and WBC in rats. 
Treatment 
Haemoglobin 
(mg.dl-1) 
RBC 
(106 /mm3) 
WBC 
(106 /mm3) 
Calcium 
(mg.dl-1) 
Control 15.3± 0.25 9.15± 0.02 11.45± 0.05  9.45 ±0.02 
Munnai ilai 
kudineer@ 50 
mg.kg-1 
16.5± 0.26* 9.50± 0.04*   9.55± 0.01*  9.21 ±0.02 
Munnai ilai 
kudineer@ 100 
mg.kg-1 
16.3± 0.15* 9.55± 0.02*   8.354± 0.32*  9.27 ±0.20 
Munnai ilai 
kudineer@ 200 
mg.kg-1 
14.7± 0.20* 8.32± 0.12* 11.45± 0.03*  9.61 ±0.13 
Munnai ilai 
kudineer@ 400 
mg.kg-1 
13.05± 0.35* 8516± 0.45*   10.55± 0.13*  9.75 ±0.02 
 
The above table no 5.1.3.g. The effect of Munnai ilai kudineer on 
haematological parameters such as HB, Calcium, RBC and WBC in rats. A study on 
the effect of Munnai ilai kudineeron haematological parameters such as Hb, RBC, 
WBC, Calcium in rats was tested. where, group I animals (GPI) treated with normal 
saline (5 ml.kg1), group II animals (GPII)  with 50 mg.kg-1 of Munnai ilai kudineer,  
group III animals (GPIII)   with 100 mg.kg-1 of Munnai ilai kudineer,   group IV 
animals (GPIV)   with 200 mg.kg-1 of Munnai ilai kudineer, and  group V animals 
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(GPV)  with 400 mg.kg-1Munnai ilai kudineer. The values are expressed as mean ± 
S.E.M. n=6. The results of group I were compared with other groups such as II, III, IV 
and V.   The statistical analysis was carried out using one way ANOVA method, 
where *P<0.05. 
Discussion 
The evaluation of sub-chronic and chronic dosing in experimental animals 
may be more relevant in determining the overall toxicity of the plant preparation.  The 
highest overall concordance of toxicity in animals in comparison with humans is with 
hematological, gastrointestinal, and cardiovascular adverse effects whiles certain 
adverse effects in humans, especially hypersensitivity and idiosyncratic reactions, are 
poorly correlated with toxicity observed in animals (Table no 5.1.3.g). 
In the present study, where the acute toxicity study of Munnai ilai kudineer 
was carried out as per OECD-423 guidelines,no mortality was observed in both the 
animals of control group as well as animals treated with a maximum dose of 2000 
mg.kg-1.   Hence, 1/10th of 2000 mg.kg-1 i.e. 200 mg.kg-1 of dose was selected as a 
minimum dose for sub-acutetoxicity study (Abu Taha Nael et al. 2008) 
The results of sub-acute toxicity study shows( Table no 5.1.3.g) that there was 
no significant change in animal behaviour due to the absence of toxicity. The animals 
treated with Munnai ilai kudineer showed normal growth pattern and body weight 
compared with control rats treated with normal saline. So the changes in body weight 
can be used as an indicator of adverse effects of drugs and chemicals (Tofovic and 
Jackson 1999; Razaet al. 2002; Teo 2002). 
The changes in enzymes like ALP, AST and ALT levels show liver 
impairment, due to toxicity (Hayes, 1989).   Serum cholesterol and proteins mainly 
regulated via synthesis in the liver and increase or decrease in serum concentrations of 
constituents suggest liver toxicity.   The results of the present study were assessed 
after 28 days of administration of Munnai ilai kudineer, and it was found that 
Munnai ilai kudineerat all concentrations do not produce liver damage. 
There was a slight decrease in plasma glucose level, when higher doses of 
Munnai ilai kudineer(400 mg.kg-1) were administered in the treated rats.. 
Analysis of blood parameters is likely to risk evaluation as the change in 
hematological system has a higher predictive value for human toxicity, when data are 
translated from animal studies (Olson et al.2000). After 28 days of treatment, there 
were no significant changes in the haematological parameters between control and 
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treated groups. No significant changes in the levels of WBC, RBC were observed 
between control and test groups following repeated administration of Munnai ilai 
kudineer. Interestingly, significant increase in the levels of hemoglobin was found in 
treatment with Munnai ilai kudineer with a higher dose of 400 mg.kg-1. The possible 
reason could be that one of the constituents Munnai ilai kudineer may increase 
absorption of iron.  
The overall results suggest that Munnai ilai kudineer are non toxic to the 
haaematopoietic and leucopoietic system. The haematopoietic and leucopoietic 
systems are the most sensitive targets for toxic compounds and an important index of 
physiological and pathological status in man and animal (Adeneyeet al. 2006).  
Therefore, it is possible to assume that the Munnai ilai kudineeris non haematotoxic 
5.1.4 PHYTOCHEMICAL ANALYSIS  
Analysis of the siddha preparation Munnai Ilai Kudineer 
The siddha preparation Munnai Ilai Kudineer was prepared and used for 
phytochemical analysis.  
Preliminary test, on the siddha preparation Munnai Ilai Kudineer was carried 
out for the presence of alkaloids, carbohydrates, glycosides, phytosterols, saponins, 
tannins, phenolic compounds, proteins and free amino acids, flavanoids, lignin, fixed 
oils and fats. The methods adopted for the estimation are as follows:  
Test for Alkaloids (Evans, 1997)  
A small segment of the siddha preparation Munnai Ilai Kudineer was mixed 
separately with a few drops of dilute hydrochloric acid and filtered. The filtrates were 
tested carefully with various alkaloidal reagents as follows:  
a) Mayer’s test (Evans, 1997): To a few ml of filtrate, a drop of Mayer’s 
reagent is added by the side of the test tube. A white or creamy precipitate indicates 
that the test as positive.  
b) Hager’s test (Wagner et al., 1996): To a few ml of filtrate, one to 2ml of 
Hager’s reagent is added. A prominent yellow precipitate indicates the test as positive.  
c) Dragendorff’s test (Waldi, 1965): To a few ml of filtrate, one to 2ml of 
Dragendorff’s reagent is added. A prominent yellow precipitate indicates the test as 
positive.  
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Test for Carbohydrates (Ramakrishnan et al., 1994)  
A small quantity of siddha preparation Munnai Ilai Kudineer was dissolved 
separately in 5ml of distilled water and filtered. The filtrate was subjected to 
Molisch’s test to detect the presence of carbohydrates. Filtrate was treated with 2-3 
drops of 1% alcoholic alpha naphthol solution and 2ml of concentrated sulphuric acid 
was added along the sides of the test tube. Appearance of brown ring at the junction 
of 2 layers shows the presence of carbohydrates. 37  
Test for Glycosides  
The siddha preparation Munnai Ilai Kudineer was hydrolyzed with 
hydrochloric acid for few h on a water bath and the hydrolysate was subjected to 
Legal’s and Borntrager’s test to detect the presence of different glycosides.  
(a) Legal’s Test: To the hydrolysate, one ml of pyridine and few drops of 
sodium nitro prusside solution were added and then it was made alkaline with sodium 
hydroxide solution. Appearance of pink to red color shows the presence of glycosides 
and aglycones.  
(b) Borntrager’s Test: Hydrolysate was treated with chloroform and the 
chloroform layer was separated. To this equal quantity of dilute ammonia solution 
was added. Ammoniacal layer acquires pink color, shows the presence of glycosides 
(Evans, 1997).  
Test for Phytosterols (Finar, 1986)  
(a) Liebermann Burchard Test: Small amount of the siddha preparation 
Munnai Ilai Kudineer was dissolved with 3ml of acetic anhydride, a few drops of 
glacial acetic acid and followed by the addition of few drops of concentrated 
sulphuric acid. Appearance of bluish green color shows the presence of phytosterols.  
(b) Salkowski Test: Small quantities of the siddha preparation Munnai Ilai 
Kudineer were dissolved in chloroform separately. This chloroform solution was 
added with few drops of concentrated sulphuric acid. The appearance of bluish green 
color shows the presence of phytosterols.  
Test for Saponins (Kokate, 1999)  
Frothing Test: The siddha preparation Munnai Ilai Kudineer was diluted 
separately with 20ml of distilled water and it was agitated on a graduated cylinder for 
15min. Absence of the foam formation shows the devoid of saponins.  
Test for Phenolic Compounds and Tannins (Mace, 1963)  
Small quantities of siddha preparation Munnai Ilai Kudineer was dissolved 
separately in water and tested for the presence of phenolic compound and tannins. In 
the process of testing and treating, the following observations were noted:  
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a) Dilute ferric chloride solution (5%) gives a dark green color.  
b) 10% aqueous potassium dichromate solution gives yellowish brown precipitate.  
c) 10% lead acetate solution gives a white precipitate.  
 Test for Proteins and Free Amino Acids (Fisher, 1968; Ruthmann, 1970)  
Small quantities of siddha preparation Munnai Ilai Kudineer was dissolved in 
few ml of water and the following reaction were carried out  
(a) Millon’s Test :To 2ml of filtrate, few drops of Millon’s reagent were 
added. A white precipitate indicates the presence of proteins (Rasch and Swift, 1960).  
(b) Ninhydrin Test: To 2ml of filtrate 2 drops of ninhydrin solution was 
added. A characteristic purple color indicates the presence of amino acids (Yasma and 
Ichikawa, 1953).  
(c) Biuret Test: An aliquot of 2ml of filtrate was treated with a drop of 2% 
copper sulphate solution. To this, 1ml of ethanol (95%) was added, followed by 
excess of potassium hydroxide pellets, Pink color in the ethanol layer indicates the 
presence of protein (Gahan, 1984).  
Test for Flavanoids  
(a) Shinoda’s Test: Small quantity of siddha preparation Munnai Ilai Kudineer 
was treated with alcohol to that a piece of magnesium was added followed by an 
addition of concentrated hydrochloric acid drop wise and heated. Appearance of 
magenta color shows the presence of flavanoids (Harborne, 1984).  
(b) Florescence Test: Small quantity of Munnai Ilai Kudineer was dissolved 
separately in alcohol and a drop of that extract was placed on Whatman filter paper 
and observed under UV light. Florescence indicates the presence of flavanoids.  
 Tests for Lignin  
Small quantities of Munnai Ilai Kudineer was dissolved separately in few ml 
of alcoholic solution of hydrochloric acid and phloroglucinol gives red color, which 
shows lignin is present.  
Tests for Fixed oils and Fats 
(a) Spot Test: A small quantity of siddha preparation Munnai Ilai Kudineer 
was placed between 2 filter papers. Oil stains produced with any extract shows the 
presence of fats and fixed oils in the Munnai Ilai Kudineer (Harborne, 1984).  
(b)Saponification Test: A small quantity of siddha preparation Munnai Ilai 
Kudineer was treated with few drops of 0.5N alcoholic potassium hydroxide along 
with 2 to 3 drops of phenolphthalein. Later the mixture is refluxed for about 2h. Soap 
formation indicates the presence of fats and fixed oils in the Munnai Ilai Kudineer. 
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PHYTOCHEMICAL STUDY OF MUNNAI ILAI KUDINEER  
The Munnai Ilai Kudineer was subjected to qualitative chemical investigation 
Details of the various tests performed for the presence of phytoconstituents is shown 
in Table 5.1.4 a. 
 
 
 
 
 
 
Tests  Munnai Ilai Kudineer 
Mayer’s test  
Dragendroff’s test 
Hager’s test 
Alkaloids Present 
Present 
Present 
Molisch test Legal’s test 
Borntrager’s test for 
anthraquinones 
Carbohydrates and 
glycosides 
Present 
Present 
Present 
Liebermann-Burchard test 
Salkowski test 
Phytosterols Present 
Present 
Shinoda test Magnesium turnings 
and hydrochloric acid (Presence 
of red color) 
 Fluorescence test 
Flavanoids Present 
 
 
Present 
Ferric chloride test  
Biuret test 
Lead acetate test 
Tannins Present 
Present 
Present 
Millon’s test  
Biuret test 
Ninhydrin test 
Proteins 
 
Present 
Present 
Present 
Spot test 
Saponification test 
Fixed oils and fats 
 
absent 
absent 
Phloroglucinol test Lignin Present 
Forthing test Saponins absent 
64 
 
5.1.5ANTIMICROBIAL ACTIVITY PROCEDURE  
Antibacterial Activity Procedure: 
Dilution :1mg in 1ml (0.1g in 1ml) 
Test Organism: 
 The test microorganisms used for antimicrobial analysis Microorganism 
namewere purchased from Microbial Type Culture Collection and Gene Bank 
(MTCC)Chandigarh.The bacterial strains were maintained on Nutrient Agar (NA) and 
fungi on Sabouraud Dextrose Agar (SDA).  
Nutrient Broth Preparation 
Pure culture from the plate were inoculated into Nutrient Agar plate and sub 
cultured at 37ºC for 24 h. Inoculum was prepared by aseptically adding the fresh 
culture into 2 ml of sterile 0.145 mol/L saline tube and the cell density was adjusted to 
0.5 McFarland turbidity standard to yield a bacterial suspension of 1.5×108 cfu/ml. 
Standardized inoculum Used for Antimicrobial test. 
Antimicrobial Test: 
The medium was prepared by dissolving 38 g of Muller Hinton Agar Medium 
(Hi Media) in 1000 ml of distilled water. The dissolved medium was autoclaved at 15 
Lbs pressure at 1210C for 15 min (pH 7.3). The autoclaved medium was cooled, 
mixed well and poured petriplates (25 ml/plate) the plates were swabbed with 
Pathogenic Bacteria culture viz.Microorganism name Finally, The Sample or Sample 
loaded Disc was then placed on the surface of Mullar-Hinton medium and the plates 
were kept for incubation at 37°C for 24 hours. At the end of incubation, inhibition 
zones were examined around the disc and measured with transparent ruler in 
millimeters. The size of the zone of inhibition (including disc) was measured in 
millimeters. The absence of zone inhibition was interpreted as the absence of activity 
(Kohner et al., 1994; Mathabe et al., 2006). The activities are expressed as resistant, if 
the zone of inhibition was less than 7 mm, intermediate (8-10 mm) and sensitive if 
more than 11 mm (Assam et al., 2010) 
ANTIFUNGi ASSAY BY DISC DIFFUSION METHOD (Bauer et al., 1966) 
Antibiotic susceptibility tests were determined by agar disc diffusion (Kirby–
Bauer) method. Fungi strains (Fungi Name) were swabbed using sterile cotton swabs 
in SDA agar plate. Up to 40 µl of each concentration of the extract were respectively 
introduced in the sterile discs using sterile pipettes. The disc was then placed on the 
surface of SDA medium and the compound was allowed to diffuse for 5 minutes and 
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the plates were kept for incubation at 22°C for 48 hours. At the end of incubation, 
inhibition zones were examined around the disc and measured with transparent ruler 
in millimeters. 
Minimum Inhibitory Concentration (MIC) Determination 
This assay consists in the determination of chemical agent spectrum of action, 
according to resistance of studied microorganisms. It was developed the 
determination of minimum inhibitory concentration (MIC) for every chemical agent, 
through the classic method of successive dilution. In twelve numbered screw tubes 
(10 x 100 mm), 1 mL of TSB (trypticase soy broth) medium was distributed for every 
tube, except for the tube number 1. The tubes were submitted to autoclave under 
constant pressure and temperature of 121 °C. For the first and the second tubes of the 
series, 1 mL of tested sanitizing agent was added; tube 2 was stirred and 1 mL was 
withdrawn and transferred for tube 3. This successive transference was repeated until 
tube 11. It was added to all flasks, except for flask number. 
 
Figuire-1 
 
Figure-2 
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Figure-3     Figure-4 
 
 
Figure-5 
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Name :
Sample received date :
Result Sending date :
 
Sample 
Code 
Staphylococcus 
aureus (G+) 
Streptococcus 
MIK 14 
PC 25            
NC - 
 
Keys 
             PC         
NC                          
 -                              
Mm                        
 G+                          
G-                           
Dr.Johny Manoji   
SCIENTIFIC OFFICER
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 Dr. N.Prakash 
 11.06.2019 
 24.06.2019 
ANTIMICROBIAL  RESULTS 
Bacteria  Strains Name 
mutans (G+) 
 
Bacillus 
subtilis(G+) 
 
 
Klebsilla 
pneumonia 
(G-) 
13 11 12 
15 25 25 
- - - 
-     Positive Control (Streptomycin) 
-    Negative Control 
-    No Zone 
-    Millimetre  
-   Gram Positive Organism 
-   Gram Negative Organism 
                                                                    INBIOTICS
 
 
 
E – coli (G-) 
10 
23 
- 
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5.1.6 BIO-CHEMICAL ANALYSIS OF MUNNAI ILAI KUDINEER 
Preparation of the extract: 
5gms of the drug is weighed accurately and placed in a 250ml clean beaker 
then 50ml of distilled water is added and dissolved well. Then it is boiled well for 
about 10 minutes. It is cooled and filtered in a 100ml volumetric flask and then it is 
made to 100ml with distilled water. This extract is taken for analysis. 
QUALITATIVE ANALYSIS 
Sl. 
No. 
Experiment Observation Inference 
1. 
TEST FOR CALCIUM: 
2ml of the above prepared extract is taken 
in a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution. 
 
No white 
precipitate is 
formed 
Absence of 
Calcium 
2. 
TEST FOR SULPHATE: 
2ml of the extract is added to 5% Barium 
chloride solution. 
 
A white 
precipitate is 
formed 
 
Indicates the 
presence of 
sulphate 
3. 
TEST FOR CHLORIDE: 
The extract is treated with silver nitrate 
solution. 
 
A white 
precipitate is 
formed 
 
Indicates the 
presence of 
chloride 
4. 
TEST FOR CARBONATE: 
The substance is treated with concentrated 
Hcl. 
 
No brisk 
effervessence is 
formed 
Absence of 
carbonate 
5. 
TEST FOR STARCH: 
The extract is added with weak iodine 
solution. 
 
No Blue colour 
is formed 
 
Absence of 
starch 
6. 
TEST FOR FERRIC IRON: 
The extract is acidified with Glacial acetic 
acid and potassium ferro cyanide. 
No blue colour is 
formed 
Absence of ferric 
iron 
7. 
TEST FOR FERROUS IRON: 
The extract is treated with concentrated 
nitric acid and ammonium thiocyanate 
solution. 
Bloodred colour 
is formed 
 
Indicates the 
presence of 
ferrous iron 
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8. 
TEST FOR PHOSPHATE: 
The extract is treated with ammonium 
molybdate and concentrated nitric acid. 
 
No yellow 
precipitate is 
formed 
Absence of 
phosphate 
9. 
TEST FOR ALBUMIN: 
The extract is treated with Esbach’s 
reagent. 
 
No yellow 
precipitate is 
formed 
Absence of 
albumin 
10. 
TEST FOR TANNIC ACID: 
The extract is treated with ferric chloride. 
 
No blue black 
precipitate is 
formed 
Absence of 
tannic acid 
11. 
TEST FOR UNSATURATION: 
Potassium permanganate solution is added 
to the extract. 
 
It gets 
decolourised 
 
Indicates the 
presence of 
unsaturated 
compound 
12. 
TEST FOR THE REDUCING SUGAR: 
4ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 
2 minutes and add 8-10 drops of the extract 
and again boil it for 2 minutes. 
 
No colour 
change occurs 
 
Absence of 
reducing sugar 
13. 
TEST FOR AMINO ACID: 
One or two drops of the extract is placed in 
a filter paper and dried well. After drying 
1% ninhydrin is sprayed over the same and 
dried it well. 
 
Violet colour is 
formed 
Indicates the 
presence of 
Amino acid 
14. 
TEST FOR ZINC: 
The extract is treated with potassium 
ferrocyanide. 
 
No white 
precipitate is 
formed 
Absence of zinc 
 
Inference: 
Indicates the presence of sulphate, chloride,  ferrous iron,  unsaturated 
compound and amino acid. 
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5.2 CLINICAL STUDY 
The results were observed regarding the following criteria by clinical trial 
study on 40 patients. 20 Out patients and 20 In patients in both sex were studied.  
Theselection  criteriaare, 
2. Age Distribution 
3. Sex Distribution 
4. Kaalam 
5. Paruva kaalam 
6. Thinai 
7. Constitution of body 
8. Gunam 
9. Religion 
10. Socio-Economical Status 
11. Food Habits 
12. Family History 
13. Occupation 
14. Aetiological Factors 
15. Mode of Onset 
16. Duration of Illness 
17. Clinical Manifestation 
18. Kanmenthiriyam 
19. Gnanendrium 
20. Kosam 
21. Condition of Mukkutram  
a).Vatham b). Pitham  c). Kapam 
22. Involvement of Udal Thathukkal 
23. Conditions of Envagai Thervugal 
24. Neer Kuri 
25. NeiKuri 
26. Radiological Findings 
27. Back Pain Functional Score Scale 
28. Gradation of results 
 1. AGE DISTRIBUTION
Table-1 illustrates the age distribution of age and its percentage.
 
Sl. 
No. 
 
Age group (In 
years) 
1. 30-35 
2. 36-40 
3. 41-50 
4. 51-60 
 Total 
 
FIGURE-1 
AGE DISTRIBUTION 
 
From the above table-1 it is observed that the highest incidence of Thandaga Vatham 
in 20 Out patient is among 
also in the age group of 51
0
1
2
3
4
5
6
7
8
9
10
30-35 36-40
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) No. of cases 
Percentage 
3 15% 4 
4 20% 2 
6 30% 4 
7 35% 10 
20 100% 20 
 
the age group of 51-60 with 35% and among 20 In patients 
-60 with 50%. 
41-50 51-60
OP Patients
IP patients
 
(%) 
20% 
10% 
20% 
50% 
100% 
 2. SEX DISTRIBUTION
Table-2 illustrates the distribution of sex and its percentage.
TABLE-2 
SEX DISTRIBUTION 
 
Sl. 
No. 
 
Sex
1. Male
2. Female
 Total
 
 
FIGURE-2 
SEX DISTRIBUTION 
 
 
From the above table-2 it is observed that among 20 Out patients 60% were 
40% were females and among 20 In patients 75% were males and 25% were females.
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
 12 60% 15 
 8 40% 5 
 20 100% 20 100%
IP
Male
Female
 
(%) 
75% 
25% 
 
 
males and 
 
 3. KAALAM 
Table-3 illustrates the distribution of kaalam and its percentage.
TABLE-3 DISTRIBUTION OF KAALAM
 
Sl. 
No. 
 
Kaalam
1. Vatham
2. Pitham
3. Kapam
 Total
 
FIGURE-3 
DISTRIBUTION OF KAALAM
 
 
From the above table-3 it is observed that the highest 
among 20 Out patients is in Pitha Kaalam with 90% and among 20 In patients, is also 
Pitha Kaalam with 85%. 
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
 2 10% 3 
 18 90% 17 
 - - - 
 20 100% 20 100%
 
incidence of Thandaga Vatham 
Pitham Kapham
op
IP
 
(%) 
15% 
85% 
- 
 
 
 4. PARUVA KAALAM 
Table-4 illustrates the distribution of paruva kaalam and its percentage.
TABLE-4 DISTRIBUTION OF PARUVA KAALAM
 
Sl. 
No. 
 
Paruva Kaalam
1. Elavenil Kaalam
2. Muthuvenil Kaalam
3. Kaar Kaalam
4. Koothir Kaalam
5. Munpani Kaalam
6. Pinpani Kaalam
 Total 
 
FIGURE-4 
DISTRIBUTION OF PARUVA KAALAM
From the above table-4 it is observed that the highest incidence of Thandaga Vatham 
among 20 Out patients is in Elavenil 
Muthuvenil Kaalam. 
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
 9 45% 1 
 4 20% 7 
 1 5% - 
 - - 5 
 6 30% 6 
 - - 1 
20 100% 20 
 
Kaalam and among 20 In patient is
 
(%) 
5% 
35% 
- 
25% 
30% 
5% 
100% 
 
 in 
op
IP
 5. THINAI 
Table-5 illustrates the distribution of thinai and its percentage.
TABLE-5 DISTRIBUTION OF THINAI
 
Sl. 
No. 
 
Thinai 
1. Kurinji 
2. Mullai 
3. Marutham 
4. Neithal 
5. Paalai 
 Total 
 
FIGURE-5 
DISTRIBUTION OF THINAI
 
 
From the above table-5 it is observed that 
among 20 Out patients were in the Marutham Thinai with 85% and among 20 In 
Patients also in Marutham Thinai with 100%.
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
- - - 
- - - 
17 85% 20 
3 15% - 
- - - 
20 100% 20 
 
highest incidence of Thandaga Vatham 
 
Marutham Neithal Paalai
OP
IP
 
(%) 
- 
- 
100% 
- 
- 
100% 
 
 6. CONSTITUTION OF
Table-6 illustrates the distribution of constitution of the body and its p
TABLE-6 
DISTRIBUTION OF CONSTITUTION OF BODY
Sl. 
No. 
 
Constitution of body
1. Vatham 
2. Vatha Pitham
3. Vatha Kapam
4. Pitham 
5. Pitha Vatham
6. Pitha Kapam
7. Kapam 
8. Kaba Vatham
9. Kaba Pitham
 Total 
 
FIGURE-6 
DISTRIBUTION OF CONSTITUTION OF BODY
From the above table-6 it is observed that
among 20 Out patients is Pitha Vatham Thegi with 55% and among 20 In patients is 
also Pitha Vatham Thegi with 60%.
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
- - - 
 7 35% 4 
 - - - 
- - - 
 11 55% 12 
 2 10% 4 
- - - 
 - - - 
 - - - 
20 100% 20 
 
 the highest incidence of Thandaga Vatham 
 
OP
IP
 
 
(%) 
- 
20% 
- 
- 
60% 
20% 
- 
- 
- 
100% 
 
 7. GUNAM 
Table-7 illustrates the distribution of gunam and its percentage.
TABLE-7 DISTRIBUTION OF GUNAM
 
Sl. 
No. 
 
Gunam 
1. Sathuvam 
2. Rajo 
3. Thamasa / Thamo
 Total 
 
FIGURE-7 
DISTRIBUTION OF GUNAM
 
From the above table-7 it is observed that the highest incidence of Thandaga Vatham 
among 20 Out patients and 20 In patients with cent percent belongs to Rajo Gunam.
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
- - - 
20 100% 20 
 - - - 
20 100% 20 
 
 
(%) 
- 
100% 
- 
100% 
 
 
 8. RELIGION 
Table-8 illustrates the distribution of religion and its percentage.
TABLE-8 DISTRIBUTION OFRELIGION
 
Sl. 
No. 
 
Religion
1. Hindu 
2. Christian
3. Muslim 
 Total 
 
FIGURE-8 DISTRIBUTION OFRELIGION
 
From the above table-8 it is observed that among 20 Out patients 95% were Hindus, 
5% wereChristians  and among 20 In patients 90% were Hindus, 5% were Christians 
and 5% were Muslims. 
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Out Patients (OP) In Patients (IP)
No. of cases 
Percentage 
(%) 
No. of 
cases 
19 95% 18 
 1 5% 1 
- - 1 
20 100% 20 
 
Christian Muslim
OP
IP
 
Percentage 
(%) 
90% 
5% 
5% 
100% 
 
 9. SOCIO-ECONOMICAL
Table-9 illustrates the distribution of socio
TABLE-9 
DISTRIBUTION OF SOCIO
 
Sl. 
No. 
 
Socio-Economical Status
1. Low income class
2. Middle income class
3. High income class
 Total 
 
FIGURE-9 
DISTRIBUTION OF SOCIO
 
From the above table-9 it is observed that the highest incidence of Thandaga Vatham 
among 20 Out patients is in Middle income class with 50% and among 20 In patients 
is in Low Income class with 70%.
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 STATUS 
-economical status and its percentage.
-ECONOMICAL STATUS 
 
Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
 6 30% 14 
 10 50% 6 
 4 20% - 
20 100% 20 
-ECONOMICAL STATUS 
 
 
 
(%) 
70% 
30% 
- 
100% 
 
 10. FOOD HABITS 
Table-10 illustrates the distribution of diet
TABLE-10 DISTRIBUTION OF FOOD
 
Sl. 
No. 
 
Food Habits
1. Vegetarian
2. Non-Vegetarian
 Total 
 
FIGURE-10 DISTRIBUTION OF FOOD
 
From the above table-10 it is observed that the highest incidence of Thandaga Vatham 
among 20 Out patients is in Non
also in Non-Vegetarians with 70%.
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 and its percentage. 
 HABITS 
 
Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
 2 10% 6 
 18 90% 14 
20 100% 20 
 HABITS 
-Vegetarians with 90% and among 20 In patients is 
 
 
(%) 
30% 
70% 
100% 
 
 11. FAMILY HISTORY
Table-11 illustrates the family history and its percentage.
TABLE-11 FAMILY HISTORY
 
Sl. 
No. 
 
Family History
1. Positive 
2. Negative 
 Total 
 
FIGURE-11 
FAMILY HISTORY 
 
From the above table-11 it is observed that among 20 Out patients and 20 In patients, 
15% have positive family history and 85% don’
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
3 15% 3 
17 85% 17 
20 100% 20 
t have positive family history.
IP
Positive
Negative
 
(%) 
15% 
85% 
100% 
 
 
 12. OCCUPATION 
Table-12 illustrates the occupation and its percentage.
TABLE-12 OCCUPATION
Sl. 
No. 
 
Occupation
1. Agricultural Labours
2. Coolie 
3. House wife 
4. Tailor 
5. Driver 
6. Business 
7. Clerk 
 Total 
 
FIGURE-12 
DISTRIBUTION OF OCCUPATION
From the above table-12 it is observed that the 
among 20 Out patients were house wives with 25% and among 20 In patients is also 
Agricultural Labours with 30%.
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
 3 15% 6 
4 20% 5 
5 25% 5 
3 15% 1 
1 5% 3 
3 15% - 
1 5% - 
20 100% 20 100%
 
highest incidence of Thandaga Vatham 
 
OP
IP
 
(%) 
30% 
25% 
25% 
5% 
15% 
- 
- 
 
 
 13. AETIOLOGICAL FACTORS
Table-13 illustrates the aetiological factors and its percentag
TABLE-13 AETIOLOGICAL FACTORS
 
Sl. 
No. 
 
Aetiological Factors
1. Age 
2. Occupation
3. Trauma 
4. Obesity 
 Total 
 
FIGURE-13 
AETIOLOGICAL FACTORS
 
From the above table-13 it is observed that the highest incidence of Thandaga Vatham 
among 20 Out patients is due to age related aetiological factors with 60% and among 
20 In patients is also due to
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e. 
 
 
Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
12 60% 13 
 4 20% 3 
- - - 
4 20% 4 
20 100% 20 100%
 
 age related aetiological factors with 65%. 
Trauma Obesity
OP
IP
 
(%) 
65% 
15% 
- 
20% 
 
 
 14. MODE OF ONSET 
Table-14 illustrates the mode of onset and its percentage.
TABLE-14 MODE OF ONSET
 
Sl. 
No. 
 
Mode of Onset
1. Acute 
2. Chronic 
 Total 
 
FIGURE-14 
MODE OF ONSET 
 
From the above table-14 it is observed that among 20 Out patients, 90% were in 
chronic state and among 20 In patients, 95% were in 
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
2 10% 1 
18 90% 19 
20 100% 20 
chronic state. 
IP
Acute
Chronic
 
(%) 
5% 
95% 
100% 
 
 15. DURATION OF ILLNESS
Table-15 illustrates the duration of illness and its percentage.
TABLE-15 DURATION OF ILLNESS
 
Sl. 
No. 
 
Duration of illness
1. 15-30 Days
2. 1-3 Months
3. 3-6 Months
4. 6-9 Months
5. 9-12 Months
6. Above 12 Months
 Total 
 
FIGURE-15 
DURATION OF ILLNESS
 
From the above table-15 it is observed that the highest duration of illness among 20 
Out patientsAbove 12 Months and 20 In patients is 1
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
 1 5% 4 
 1 5% 5 
 5 25% 5 
 1 5% 1 
 5 25% 2 
 7 35% 3 
20 100% 20 
 
-6 Months. 
3-6 
Months
6-9 
Months
9-12 
Months
Above 12 
Months
OP
IP
 
(%) 
20% 
25% 
25% 
5% 
10 
15% 
100% 
 
 16. CLINICAL MANIFESTATION
Table-16 illustrates the clinical manifestation and its percentage.
TABLE-16 CLINICAL MAN
 
Sl. 
No. 
 
Clinical Manifestation
1. Low back pain
2. Radiating pain
3. Restricted movements
4. Stiffness 
5. Tenderness 
6. 
Exacerbation of pain on 
movements 
7. Numbness 
 
FIGURE-16 
CLINICAL MANIFESTATION
From the above table-16 it is observed that, among 20 Out patients, 100% of cases 
have low back pain and exacerbation of pain on movements. 85%  have radiating 
pain, 45% have restricted movements, 35% have stiffness, 35% have tenderness and 
50% have numbness. Among 20 
radiating pain and exacerbation of pain on movements. 55% have restricted 
86 
 
 
IFESTATION 
 
Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%)
 20 100% 20 100%
 17 85% 20 100%
 9 45% 11 55%
7 35% 9 45%
10 50% 5 25%
20 100% 20 100%
6 30% 7 35%
 
Inpatients 100% of cases have low back pain, 
 
 
 
 
 
 
 
 
 
 
 movements, 45% have stiffness, 25% have tenderness and 35% have numbness.
17. KANMENTHIRIYAM
Table-17 illustrates the kanmen
TABLE-17 KANMENTHIRIYAM
 
Sl. 
No. 
 
Kanmenthiriyam
1. Kai 
2. Kaal 
3. Vai 
4. Eruvai 
5. Karuvai 
 
FIGURE-17 
KANMENTHIRIYAM 
 
From the above table-17 it is observed that among 20 Out patients, 85% were affected 
in Kaal and 35% in Eruvai. Among 20 In patients 100% were affected in Kaal and 
25% in Eruvai. 
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thiriyam and its percentage. 
 
 
Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%)
- - - -
17 85% 20 100%
- - - -
7 35% 5 25%
- - - -
Vai Eruvai Karuvai
OP
IP
 
 
 
 
 
 
 
 
 
  
18. GNANENDRIUM 
Table-18 illustrates the gnanendrium and its percentage.
TABLE-18 GNANENDRIUM
 
Sl. 
No. 
 
Gnanendrium 
1. Mei 
2. Vaai 
3. Kan 
4. Mooku 
5. Sevi 
 
FIGURE-18 
GNANENDRIUM 
 
From the above table-18 it is observed that, among 20 Out patients, 25% were 
affected in Mei, Among 20 In patients 30% were affected in Mei.
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%)
5 25% 6 30%
- - - - 
- - - - 
- - - - 
- - - - 
 
Kan Mooku Sevi
OP
IP
 
 
 
 
 19. KOSAM 
Table-19 illustrates the kosam and its percentage.
TABLE-19 KOSAM 
 
Sl. 
No. 
 
KOSAM 
1. Annamaya Kosam
2. Pranamaya Kosam
3. Manomaya Kosam
4. Vingnanamaya Kosam
5. Anandamaya Kosam
 
FIGURE-19 
KOSAM 
 
From the above table-19 it is observed that among 20 Out patients 100% were 
affected with Vingnanamaya Kosam and 30% were affected with Annamaya Kosam. 
Among 20 In patients, 100% were affected with Vingnanamaya Kosam and 25% were 
affected with Annamaya Kosam.
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
 6 30% 5 
 - - - 
 - - - 
 20 100% 20 
 - - - 
 
OP
IP
 
(%) 
25% 
- 
- 
100% 
- 
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20 (a).CONDITION OF MUKKUTRAM (a). VATHAM: 
Table-20 (a) illustrates the condition of vatham and its percentage. 
TABLE-20 (a) 
CONDITION OF VATHAM 
 
Sl. 
No. 
 
Condition of Vatham 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Piraanan - - - - 
2. Abaanan 7 35% 5 25% 
3. Viyaanan 20 100% 20 100% 
4. Uthaanan - - - - 
5. Samaanan 20 100% 20 100% 
6. Naagan - - - - 
7. Koorman 2 10% - - 
8. Kirukaran 6 30% 5 25% 
9. Devathathan 20 100% 20 100% 
10. Dhananjayan - - - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE-20 (a) 
CONDITION OF VATHAM
 
From the above table-20 a it is observed that among 20 Out patients 100% were 
affected in Viyaanan, Samaanan and Devathathan; 35% were affected in Abaanan; 
10% were affected in Koorman; 30% were affected in Kirukaran; Among 20 In 
patients 100% were affected in Viyaanan, Samaanan and Devathathan; 25% were 
affected in Abaanan. 
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 20 (b). PITHAM 
Table-20 (b) illustrates the condition of pitham and its percentage.
TABLE-20 (b) CONDITION OF PITHAM
 
Sl. 
No. 
 
Condition of Pitham
1. Analagam 
2. Ranjagam 
3. Sathagam 
4. Prasagam 
5. Aalosagam 
 
FIGURE-20 (b) 
CONDITION OF PITHAM
 
From the above table-20 b it is observed that among 20 Out patients, 100% were 
affected in Sathagam; 30% were affected in Analagam; 25% were affected in 
Ranjagam; Among 20 In patients, 100% were affected in Sathagam; 25% were 
affected in Analagam; 10% were affected in Ranjagam.
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage
(%)
6 30% 5 25%
5 25% 2 10%
20 100% 20 100%
- - - 
- - - 
 
 
Sathagam Prasagam Aalosagam
OP
IP
 
 
 
 
 
 
- 
- 
 
 20 (c).KAPAM 
Table-20 (c) illustrates the condition of Kapam and
TABLE-20 (c) CONDITION OF KAPAM
 
Sl. 
No. 
 
Condition of Kapam
1. Avalambagam
2. Kilethagam
3. Pothagam 
4. Tharpagam
5. Santhigam
 
FIGURE-20 (c) 
CONDITION OF KAPAM
 
From the above table-20 c it is observed that among 20 Out patients, 100% were 
affected in Santhigam; 30% were affected in Kilethagam. Among 20 
were affected in Santhigam; 25% were affected inKilethagam.
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 its percentage. 
 
 
Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
 - - - 
 6 30% 5 
- - - 
 - - - 
 20 100% 20 
 
Inpatients, 100% 
 
OP
IP
 
(%) 
- 
25% 
- 
- 
100% 
 
 21. INVOLVEMENT OF UDAL
Table-21 illustrates the involvement of udal thathukkal and its percentage.
TABLE-21 INVOLVEMENT OF UDAL 
 
Sl. 
No. 
 
Involvement of Udal 
Thathukkal
1. Saaram 
2. Senneer 
3. Oon 
4. Kozhuppu 
5. Enbu 
6. Moolai 
7. Sukkilam / Suronitham
 
FIGURE-21 
INVOLVEMENT OF UDAL THATHUKKAL
 
From the above table-21 it is observed that among 20 Out patients and 20 In patients 
cent per cent were affected in Saaram, Kozhuppu, Enbu. 
were affected in Senneer and in 20 In patients, 10% were affected in Senneer.
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 THATHUKKAL 
THATHUKKAL 
 
Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
20 100% 20 
5 25% 2 
- - - 
20 100% 20 
20 100% 20 
- - - 
 - - - 
 
Among 20 Out patients, 25% 
OP
IP
 
 
(%) 
100% 
10% 
- 
100% 
100% 
- 
- 
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22. CONDITIONS OF ENVAGAI THERVUGAL 
Table-22 illustrates the envagai thervugal and and its percentage. 
TABLE-22 
CONDITIONS OF ENVAGAI THERVUGAL 
 
Sl. 
No. 
 
Conditions of Envagai 
Thervugal 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Naadi (Thontha Naadi)     
 1). Vatha Pitham 7 35% 4 20% 
 2). Vatha Kapam - - - - 
 3). Pitha Vatham 11 55% 12 60% 
 4). Pitha Kapam 2 10% 4 20% 
 5). Kaba Vatham - - - - 
 6). Kaba Pitham - - - - 
2. Sparisam 5 25% 6 30% 
3. Naa - - - - 
4. Niram - - - - 
5. Mozhi - - - - 
6. Vizhi - - - - 
7. Malam 7 35% 5 25% 
8. Moothiram - - - - 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE-22 
CONDITIONS OF ENVAGAI
 
From the above table-22  it is observed that among 20 Out patients, 35% have Vatha 
Pitha Naadi,  55% have Pitha Vatha Naadi and 10% have Pitha Kaba Naadi; 25% 
were affected in Sparisam; 35% were affected
have Vatha Pitha Naadi,  60% have Pitha Vatha Naadi and 20% have Pitha Kaba 
Naadi ; 30% were affected in Sparisam;  25% were affected inMalam.
0
2
4
6
8
10
12
96 
 THERVUGAL 
 in  Malam. Among 20  In patients, 20% 
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 23. NEERKURI 
Table-23 illustrates the neer kuri and its percentage.
TABLE-23 NEERKURI
 
Sl. 
No. 
 
Neer Kuri
1. Niram
2. Manam
3. Edai 
4. Nurai 
5. Enjal 
 
FIGURE-23 
NEERKURI 
 
From the above table-23 it is observed that among 20 Out patients, 30% were affected 
in Niram. Among 20 In patients, 35% were affected in Niram.
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Out Patients (OP) In Patients (IP)
No.of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
 6 30% 7 
 - - - 
- - - 
- - - 
- - - 
 
Edai Nurai Enjal
OP
IP
 
(%) 
35% 
- 
- 
- 
- 
 
 24. NEIKURI 
Table-24 illustrates the neikuri and its percentage.
TABLE-24 NEIKURI 
 
Sl. 
No. 
 
Nei Kuri 
1. 
Vatha Neer / Spreading 
like snake 
2. 
 Pitha Neer / Spreading 
like ring 
3. 
 Kapa Neer / Spreading 
like pearl 
4. Thontha Neer
5. Asathiya Nei Kurigal
 
FIGURE-24 
NEIKURI 
From the above table-24 it is observed that among 20 Out patients, 70% have Vatha 
Neer; 10% Pitha Neer; 10% Ka
65% have Vatha Neer; 15% Pitha Neer; 10% Kaba Neer and 10% Thontha Neer.
0
2
4
6
8
10
12
14
Vatha Neer / 
Spreading like 
snake
Pitha Neer / 
Spreading like 
98 
 
Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
14 70% 13 
2 10% 3 
2 10% 2 
 2 10% 2 
 - - - 
pa Neer and 10% Thontha Neer. Among 20 In patiens, 
ring
Kaba Neer 
Spreading like 
ring
Thontha Neer Asathiya Nei 
Kurigal
 
(%) 
65% 
15% 
10% 
10% 
- 
 
 
OP
IP
 25. RADIOLOGICAL FINDINGS
Table-25 illustrates radiological findings and its percentage.
TABLE-25 RADIOLOGICAL FINDINGS
 
Sl. 
No. 
 
 
Radiological Findings
1. Degenerative changes
2. Osteophytic changes
3. Reduced in IVD space
4. Altered lordosis
 
FIGURE-25 
RADILOGICAL FINDINGS
 
From the above table-25 it is observed that among 20 Out patients and 20 In patients, 
cent percent have degenerative and osteophytic changes. Among 20 Out patients, 10% 
have reduced IVD space. Among 20 In patients, 15% have reduced IVD space; 10% 
have reduced lordosis. 
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Out Patients (OP) In Patients (IP)
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%)
 20 100% 20 100%
 20 100% 20 100%
 2 10% 3 15%
 - - 2 10%
 
Reduced in 
IVD space
Altered 
lordosis
OP
IP
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26. ASSESSMENT OF OUTCOME 
(a) Cardinal Signs 
Table-26 (a) (i) illustrates assessment of out come by cardinal signs (Out patients). 
TABLE-26 (a) (i) 
CARDINAL SIGNS ASSESSMENT-OUT PATIENTS 
(n=20) (List wise) 
 
 
Sl. 
No. 
 
 
Cardinal Signs 
Out patients 
Be
fo
re
 
Tr
ea
tm
en
t 
A
fte
r 
Tr
ea
tm
en
t 
 
 
S.D 
 
 
S.E. 
 
 
T 
 
 
P 
 
 
Result 
1. Low back pain 2.75 0.65 1.23 0.35 5.92 <0.001 Improved 
2. Radiating pain 2.25 0.75 1.21 0.21 7.09 <0.001 Improved 
3. 
Restricted 
movements 
1.20 0.55 0.94 0.20 3.11 <0.01 Improved 
4. Stiffness 0.90 0.60 0.99 0.12 2.34 <0.05 Improved 
5. Tenderness 0.90 0.45 0.69 0.11 3.94 <0.001 Improved 
6. Numbness 2.55 2.85 0.37 0.10 2.85 <0.05 Improved 
Improved 
Among 20 Out patients, 100% had the history of low back pain; 40% had 
radiatingpainofGrade2,35%ofGrade3&10%ofGrade4;10%hadrestrictedMovementsof
Grade4,15%ofGrade3,15%ofGrade2,5%ofGrade1;20%hadstiffness of Grade 3, 15 % 
of Grade 2; 5% had tenderness of Grade 3, 30% of Grade2& 15% of Grade 1; 15% of 
numbness of Grade 2 & 15% of Grade 1. After treatment, the results are statistically 
Improved at various P values. 
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Table-26 (a) (ii) illustrates assessment of out come by cardinal signs (In patients). 
TABLE-26 (a) (ii) 
CARDINAL SIGNS ASSESSMENT-IN PATIENTS 
(n=20) (List wise) 
 
 
Sl. 
No. 
 
 
Cardinal Signs 
In patients 
Be
fo
re
 
Tr
ea
tm
en
t 
A
fte
r 
Tr
ea
tm
en
t 
 
 
S.D 
 
 
S.E. 
 
 
T 
 
 
P 
 
 
Result 
1. Low back pain 3.00 0.50 0.95 0.22 11.18 <0.001 Improved 
2. Radiating pain 2.80 0.80 1.32 0.27 7.36 <0.001 Improved 
3. 
Restricted 
movements 
1.40 0.50 0.95 0.20 4.41 <0.001 Improved 
4. Stiffness 1.20 0.60 1.05 0.19 3.04 <0.01 Improved 
5. Tenderness 0.45 0.25 0.64 0.09 2.17 <0.05 Improved 
6. Numbness 2.50 2.85 0.37 0.10 3.19 <0.05 Improved 
Improved 
Among 20 In patients, 100% had the history of low back pain; 55% had radiating pain 
of Grade2, 20% of Grade3 & 15% of Grade4; 10% of Grade1; 20%  had restricted 
movements of Grade3, 15% of Grade2, 10% of Grade4, 10% of Grade1; 10% had 
stiffness of Grade 3, 10 % of Grade 2; 10% of Grade 1; 10% of had tenderness of 
Grade 1, 10% of Grade 2, 5% of Grade 3; 20% had numbness of Grade 2 & 15% of 
Grade 1. After treatment, the results are statistically Improved at various Pvalues. 
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Table-26 (b) (i) illustrates assessment of out come by range of motion (Out patients). 
TABLE-26 (b) (i) 
RANGE OF MOTION-OUT PATIENTS 
(n=20) (List wise) 
 
 
Sl. 
No. 
 
 
Range of Motion 
Out patients 
Be
fo
re
 
Tr
ea
tm
en
t 
A
fte
r 
Tr
ea
tm
en
t 
 
 
S.D 
 
 
S.E. 
 
 
T 
 
 
P 
 
 
Result 
1. Flexion 0.55 1.70 0.47 0.08 14.03 <0.001 Improved 
2. Extension 0.50 1.65 0.59 0.10 10.50 <0.001 Improved 
3. Rotation 0.30 1.65 0.49 0.20 6.46 <0.001 Improved 
4. Lateral flexion 0.32 1.50 0.51 0.09 12.59 <0.001 Improved 
Among 20 Out patients, 100% of cases has history of difficulty in the range of 
movements. Flexion-30% with Grade 1 & 70% with Grade 0, Extension-35% with 
Grade 1 & 65% with Grade 0.Rotation-55% with Grade 1 & 45% with Grade 0, 
Lateral flexion-30% with Grade 1 & 70% with Grade 0. After treatment, the results 
are satistically was ImprovedatP<0.001. 
 
Table-26 (b) (ii) illustrates assessment of out come by range of motion (In patients). 
TABLE-26 (b) (ii) 
RANGE OF MOTION-IN PATIENTS 
(n=20) (List wise) 
 
 
Sl. 
No. 
 
 
Range of motion 
In patients 
Be
fo
re
 
Tr
ea
tm
en
t 
A
fte
r 
Tr
ea
tm
en
t 
 
 
S.D 
 
 
S.E. 
 
 
T 
 
 
P 
 
 
Result 
1. Flexion 0.50 1.30 0.57 0.09 8.71 <0.001 Improved 
2. Extension 0.55 1.35 0.67 0.09 8.71 <0.001 Improved 
3. Rotation 0.50 1.20 0.77 0.10 6.65 <0.001 Improved 
4. Lateral flexion 0.45 1.10 0.31 0.13 4.95 <0.001 Improved 
 
Among 20 Out patients, 100% had the difficulty in active range of movements. 
Flexion-50% with Grade 1 & 50% with Grade 0, Extension-55% with Grade 1 & 45% 
with Grade 0, Rotation-50% with Grade 1 & 50% with Grade 0, Lateral flexion-45% 
with Grade 1 & 55% with Grade 0. After treatment the results  are statistically 
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Improved atP<0.001. 
26. (c) (i) Back Pain Functional Scale Score 
Table-26 (c) (i) illustrates back pain functional scale score in percentage. 
TABLE-26 (c) (i) 
BACK PAIN FUNCTIONAL SCORE SCALE 
 
 
 
 
Sl. 
No. 
 
 
 
Assessment of 
Outcome (Pain 
Score) 
Before Treatment After Treatment 
Out Patients 
(OP) 
In Patients 
(IP) 
Out 
Patients 
(OP) 
In  Patients 
(IP) 
N
o
.
 
o
f c
a
se
s 
Pe
rc
en
ta
ge
 
(%
) 
N
o
.
 
o
f c
a
se
s 
Pe
rc
en
ta
ge
 
(%
) 
N
o
.
 
o
f c
a
se
s 
Pe
rc
en
ta
ge
 
(%
) 
N
o
.
 
o
f c
a
se
s 
Pe
rc
en
ta
ge
 
(%
) 
1. ≤30 20 100% 20 100% 2 10% 2 10% 
2. 31-40 - - - - 2 10% 4 20% 
3. 41-50 - - - - 3 15% - - 
4. 51-60 - - - - 13 65% 14 70% 
Minimum Score-0, Maximum Score-60 
 
Pain Score Improvement 
≤30 NO 
31-40 Mild 
41-50 Moderate 
51-60 Good 
 
Reference: 
Stratford PW Binkley JM et al. Development and initial validation of the Back 
pain Functional Scale. Spine.2000; 2095-2102 (Appendix-A Page: 2101) 
From the above table, it is observed that before treatment among 20 Out 
patients and 20 In patients cent percent were with pain score ≤30. After treatment, 
among 20 Out patients 65% have good improvement; 15%: moderate imporevement; 
10% mild improvement; 10% no improvement. Among 20 In patient 70% have good 
improvement; 20% mild improvement; 10% no improvement. 
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FIGURE-26 (c) (i) 
BACK PAIN FUNCTIONAL SCALE SCORE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
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BPFSS 
After Treatment BeforeTreatment 
IP OP IP OP 
Percentage(%) Percentage(%) 
Less than 30 
 
Percentage (%) Percentage (%) 
51to60 
41 to 50 
31 to 40 10% 10% 
0% 0% 
0% 10% 0% 0% 30% 
20% 
10% 
0% 
20% 0% 0% 
15% 
100% 
90% 
80% 
70% 
60%
50% 
40% 
65% 
70% 100% 100% 
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Table-26 (c) (ii) illustrates BPFSS-Out Patients. 
TABLE-26 (c) (ii) BPFSS-OUT PATIENTS 
 
Sl. 
No. 
 
 
Out patients 
N
 
 
M
in
im
u
m
 
 
M
a
x
im
u
m
 
 
 
Mean 
 
 
SD 
 
 
SEM 
1. Before treatment 20 10.00 30.00 21.85 5.40 1.21 
2. After treatment 20 24.00 59.00 48.20 10.14 2.27 
 N (list wise) 20      
 
Correlations 
   
Before 
treatment 
After 
Treatment 
1. Before treatment Pearson correlations 1 0.821** 
  Sig. (2tailed)  0.000 
  N 20 20 
2. After treatment Pearson correlations 0.821** 1 
  Sig. (2tailed) 0.000  
  N 20 20 
**Correlation is significant at the 0.01 level (2-tailed) 
Pearson correlation (γ) before and after treatment is 0.821. One way analysis  if 
variance ANOVA; p-value followed to be less than 0.001 is considered to be 
extremely statisticallysignificant.There is strong evidence (t=18.524, P<0.001) that 
the clinical trial drug improves the Thandaga Vatham patients. In this data set, we 
could get a mean paired difference - 26.35, df=19 with the confidence interval of 95% 
the null hypothesis is rejected, since P<0.001. The relation is positive which means 
that as one variable  goes up or down so will the otherone. 
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Table-26 (c) (iii) illustrates BPFSS-In Patients. 
TABLE-26 (c) (iii) BPFSS-INPATIENTS 
(n=20) (List wise) 
 
Sl. 
No. 
In patients N
 
 
M
in
im
u
m
 
 
M
a
x
im
u
m
 
 
 
Mean 
 
 
SD 
 
 
SEM 
1. Before treatment 20 10.00 28.00 19.10 5.34 1.20 
2. After treatment 20 17.00 58.00 46.50 12.26 2.74 
 
Correlations 
(n=20) (List wise) 
   
Before 
treatment 
After 
Treatment 
1. Before treatment Pearson correlations 1 0.413** 
  Sig. (2tailed)  0.000 
  N 20 20 
2. After treatment Pearson correlations 0.413** 1 
  Sig. (2tailed) 0.000  
  N 20 20 
**Correlation is significant at the 0.01 level (2-tailed) 
Pearson correlation (γ) before and after treatment among In patient is 0.413. One way 
analysis if variance ANOVA; p-value followed to be less than 0.0001 is considered to 
be extremely statistically significant. 
There is strong evidence (t=10.9651, P<0.001) that the clinical trial drug improves the 
patients. Mean paired difference-27.10,df=19 with 95% confidence interval. The null 
hypothesis is rejected, since P<0.001 suggesting the relationship is a positive. 
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27. GRADATION OFRESULTS 
Table-27 illustrates Gradation of Results and its percentage. 
TABLE-27 GRADATION OF RESULTS 
 
Sl. 
No. 
 
Results 
Out Patients (OP) In Patients (IP) 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Good response 13 65% 14 70% 
2. Moderate response 5 25% 4 20% 
3. Poor response 2 10% 2 10% 
 Total 20 100% 20 100% 
 
FIGURE-27 
GRADATION OF RESULTS 
 
 
 
 
 
 
 
 
 
 
 
From the above table, it is observed that among 20 Out patients, 65% showed good 
response; 25% moderate response; 10% poor response. Among 20 In patients, 70% 
showed good response; 20% moderate response; 10% poor response. 
Poor response Moderate response 
RESULTS 
Good response 
10% 10% 
20% 
25% 
OP% 
IP % 
65% 
70% 
60% 
50% 
40% 
30% 
20% 
10% 
0% 
70% 
P
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e
n
ta
ge
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TABLE-28 (a) 
LABORATORY INVESTIGATION (OUT PATIENTS) 
 
 
Sl. 
No. 
 
 
Out 
Patient 
Haematological Report Urine Analysis 
Before Treatment AfterTreatment Before Treatment After Treatment 
TC DC ESR 
 
H
b
%
 
(
g
m
s
)
 TC DC ESR 
 
H
b
%
 
(
g
m
s
)
 
A
l
b
.
 
S
u
g
.
 
 
Dep- Epi. Cells / 
Puscells A
l
b
.
 
S
u
g
.
 
D
e
p
-
 
E
p
i
.
 
C
e
l
l
s
/
 
P
u
s
c
e
l
l
s
 
C
e
l
l
s
 
/
 
c
u
 
m
m
 
P
 
L
 
E
 
½
 
H
r
.
 
1
 
H
r
.
 
C
e
l
l
s
 
/
 
c
u
 
m
m
 
P
 
L
 
E
 
½
 
H
r
.
 
1
 
H
r
.
 
1. 34781 6800 60 37 3 10 24 8.5 7000 61 34 5 9 15 9.1 NIL NIL 2-3PUS CELLS NIL NIL NAD 
2. 35245 9400 68 23 7 3 15 10.5 9700 71 23 6 2 14 11.2 NIL NIL NAD NIL NIL NAD 
3. 35281 9100 66 32 6 4 9 12.4 9400 65 29 6 5 10 12.8 NIL NIL NAD NIL NIL NAD 
4. 35574 5900 56 38 6 15 32 9.4 6000 62 34 4 3 5 10.5 NIL NIL 1-3 EPI CELLS NIL NIL NAD 
5. 40506 8400 64 36 5 3 7 12.2 8600 65 30 7 3 6 12.4 NIL NIL NAD NIL NIL NAD 
6. 42877 8200 66 30 4 4 12 10.7 8400 67 30 5 3 9 11.2 NIL NIL NAD NIL NIL NAD 
7. 46407 8300 70 24 3 7 16 12.8 8600 72 24 4 8 14 13.0 NIL NIL NAD NIL NIL NAD 
8. 47318 9300 64 38 2 9 15 11.2 9200 61 36 3 8 12 11.5 NIL NIL NAD NIL NIL NAD 
9. 48538 8200 66 28 4 8 12 12 8400 68 29 5 9 12 12.3 NIL NIL 1-2PUS CELLS NIL NIL NAD 
10. 51412 8900 64 32 4 9 17 12.5 9000 66 31 3 8 16 12.3 NIL NIL NAD NIL NIL NAD 
11. 62571 9400 66 30 4 5 15 11.0 9600 67 31 2 4 13 11.10 NIL NIL NAD NIL NIL NAD 
12. 63624 9500 60 34 6 4 14 11.0 9400 62 33 5 3 9 11.4 NIL NIL NAD NIL NIL NAD 
13. 64180 7800 62 34 6 4 8 11.8 7900 64 33 6 3 6 12.2 NIL NIL NAD NIL NIL NAD 
14. 70364 9200 60 38 2 2 4 12.6 9300 63 34 3 2 4 12.7 NIL NIL 1-2 PUS CELLS NIL NIL NAD 
15. 106698 8600 70 26 4 9 14 12.2 8700 71 24 5 7 12 12.5 NIL NIL NAD NIL NIL NAD 
16. 108637 8400 62 36 2 7 14 12.5 8900 62 35 3 5 11 13.1 NIL NIL NAD NIL NIL NAD 
17. 3316 8800 62 33 7 3 9 10.9 9000 61 33 6 2 8 11.5 NIL NIL NAD NIL NIL NAD 
18. 4418 6900 64 34 2 5 15 13.4 7000 65 32 3 4 12 13.6 NIL NIL NAD NIL NIL NAD 
19. 7908 8900 61 36 3 9 15 10.1 8800 62 34 4 8 13 11.0 NIL NIL 1-3EPI CELLS NIL NIL NAD 
20. 9165 7600 62 30 6 7 17 11.0 7900 65 30 5 6 14 11.4 NIL NIL NAD NIL NIL NAD 
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TABLE-28 (b) 
LABORATORY INVESTIGATION (IN PATIENTS) 
 
 
Sl. 
No. 
 
 
In 
Patient 
No. 
Haematological Report Urine Analysis 
Before Treatment AfterTreatment Before Treatment After Treatment 
TC DC ESR 
 
H
b
%
 
(
g
m
s
)
 
TC DC ESR 
 
H
b
%
 
(
g
m
s
)
 
A
l
b
.
 
S
u
g
.
 
 
Dep- Epi. Cells / 
Puscells A
l
b
.
 
S
u
g
.
 
D
e
p
-
 
E
p
i
.
 
C
e
l
l
s
/
 
P
u
s
c
e
l
l
s
 
C
e
l
l
s
 
 
/
 
c
u
 
m
m
 
P
 
L
 
E
 
½
 
H
r
.
 
1
 
H
r
.
 
C
e
l
l
s
 
/
 
c
u
 
m
m
 
P
 
L
 
E
 
½
 
H
r
.
 
1
 
H
r
.
 
1. 1503 7000 54 44 2 2 6 10.2 7200 60 38 2 2 4 11.2 NIL NIL NAD NIL NIL NAD 
2. 1588 8900 58 34 8 6 9 13.0 9000 62 32 6 4 8 13.2 NIL NIL NAD NIL NIL NAD 
3. 1794 10200 65 30 5 9 14 13.4 10000 64 32 4 7 12 13.3 NIL NIL NAD NIL NIL NAD 
4. 1811 9600 72 26 2 10 20 10.7 9800 73 24 2 8 16 11.3 NIL NIL 1-2 Pus Cells NIL NIL NAD 
5. 1892 8600 60 37 3 9 20 11.5 9200 65 33 2 3 6 12.2 NIL NIL 1-2 Pus Cells NIL NIL NAD 
6. 1956 9800 70 21 9 6 12 12.9 8400 63 35 2 6 12 13.2 NIL NIL NAD NIL NIL NAD 
7. 2042 9100 79 20 1 8 20 13.2 9300 79 22 1 6 14 13.2 NIL NIL NAD NIL NIL NAD 
8. 2043 6500 67 30 3 6 16 13.5 6800 68 33 2 3 6 13.5 NIL NIL NAD NIL NIL NAD 
9. 2784 9000 69 23 8 8 13 12.4 9100 70 26 4 6 10 12.6 NIL NIL NAD NIL NIL NAD 
10. 2799 7500 65 31 4 3 6 12.9 8000 63 33 4 4 8 12.8 NIL NIL NAD NIL NIL NAD 
11. 2832 9100 57 40 3 4 8 11.9 9300 59 39 2 3 7 12.0 NIL NIL NAD NIL NIL NAD 
12. 2845 6800 63 30 7 9 15 13.0 7000 64 35 1 5 13 12.9 NIL NIL 1-2Epi Cells NIL NIL NAD 
13. 3079 7800 69 24 7 8 12 10.8 7900 65 30 5 6 11 10.8 NIL NIL NAD NIL NIL NAD 
14. 3142 8900 69 29 2 4 9 12.4 9000 67 36 1 2 6 12.8 NIL NIL NAD NIL NIL NAD 
15. 87 5900 50 49 1 2 4 10.2 6500 54 45 1 2 4 11.4 NIL NIL NAD NIL NIL NAD 
16. 101 7400 59 37 4 7 15 11.9 7800 59 38 3 4 8 12.2 NIL NIL NAD NIL NIL NAD 
17. 110 8400 65 33 2 4 10 10.3 8600 67 27 1 3 10 10.8 NIL NIL NAD NIL NIL NAD 
18. 118 7800 71 23 6 2 6 14.2 8100 71 35 6 2 6 14.2 NIL NIL NAD NIL NIL NAD 
19. 126 8800 79 13 8 9 18 14.1 9000 72 29 4 4 9 14.1 NIL NIL NAD NIL NIL NAD 
20. 504 7100 67 27 6 10 20 13.0 7400 64 27 2 6 11 13.3 NIL NIL NAD NIL NIL NAD 
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TABLE-29 (a) 
LABORATORY INVESTIGATION (OUT PATIENTS) 
Sl. 
No. 
 
OP No. 
Before Treatment After Treatment 
Blood Sugar 
(R) 
Blood 
Urea 
Serum 
cholesterol 
Serum Uric 
acid 
Serum 
Creatinine 
Blood Sugar 
(R) 
Blood 
Urea 
Serum 
cholesterol 
Serum Uric 
acid 
Serum 
Creatinine 
1. 34781 101 32 160 4.00 0.80 100 29 146 3.98 0.70 
2. 35245 102 29 141 4.00 1.00 98 27 137 4.10 0.80 
3. 35281 120 27 169 3.00 0.80 115 27 166 3.00 0.80 
4. 35574 91 22 145 3.50 0.50 134 19 128 3.47 0.70 
5. 40506 129 24 119 3.00 0.60 86 25 122 3.10 0.50 
6. 42877 101 19 147 3.70 0.80 100 18 140 3.70 0.70 
7. 46407 129 25 187 4.20 0.90 117 26 189 4.20 0.70 
8. 47318 89 24 190 4.30 0.50 80 23 182 4.30 0.50 
9. 48538 94 23 132 2.50 0.80 85 21 140 2.49 0.80 
10. 51412 82 22 179 4.40 0.50 121 20 183 4.35 0.60 
11. 62571 96 21 170 3.00 0.90 116 22 168 2.99 0.80 
12. 63624 91 18 165 3.50 0.40 101 16 160 3.49 0.40 
13. 64180 90 20 164 3.60 0.70 86 18 154 3.58 0.70 
14. 70364 114 21 189 3.24 0.70 109 19 178 3.21 0.60 
15. 106698 90 20 146 3.40 0.60 122 20 161 3.39 0.70 
16. 108637 75 25 118 5.00 1.00 99 23 128 4.89 0.90 
17. 3316 94 32 163 4.52 0.80 132 30 165 4.47 0.80 
18. 4418 112 24 109 3.80 0.80 105 25 107 3.81 0.90 
19. 7908 126 24 178 3.20 0.90 99 26 176 3.00 0.80 
20 9165 98 30 189 3.00 1.00 116 27 185 3.10 0.70 
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TABLE-29 (b) 
LABORATORY INVESTIGATION (IN PATIENTS) 
Sl. 
No. 
 
IP No. 
Before Treatment After Treatment 
Blood Sugar 
(R) 
Blood 
Urea 
Serum 
cholesterol 
Serum 
Uric acid 
Serum 
Creatinine 
Blood 
Sugar (R) Blood Urea 
Serum 
cholesterol 
Serum 
Uric acid 
Serum 
Creatinine 
1. 1503 87 37 197 5.20 1.00 82 32 180 5.00 0.50 
2. 1588 105 26 160 3.80 0.60 95 22 158 3.50 0.70 
3. 1794 93 28 193 4.60 0.70 114 26 186 4.50 0.80 
4. 1811 70 32 140 4.00 0.90 70 30 136 3.80 1.00 
5. 1892 105 19 120 2.20 0.80 136 21 118 2.20 0.70 
6. 1956 120 24 188 3.00 1.00 102 25 174 3.10 0.80 
7. 2042 72 23 175 2.80 0.60 70 24 163 2.70 0.50 
8. 2043 86 27 163 4.50 0.60 80 24 177 4.60 0.50 
9. 2784 96 21 180 3.60 0.80 92 20 176 3.50 0.60 
10. 2799 105 26 200 4.40 0.50 111 24 197 4.60 0.40 
11. 2832 103 20 189 5.20 0.20 125 23 182 5.50 0.30 
12. 2845 133 30 185 4.30 0.60 91 32 180 4.70 0.70 
13. 3079 109 33 192 4.10 0.80 117 31 194 4.60 0.90 
14. 3142 85 19 156 3.60 0.80 83 18 149 3.40 0.60 
15. 87 99 17 142 3.90 1.00 97 20 155 3.20 0.90 
16. 101 111 27 164 4.00 0.70 80 24 170 3.80 0.80 
17. 110 92 15 200 3.90 0.50 92 17 196 4.10 0.40 
18. 118 102 30 130 4.30 0.80 100 27 124 4.20 0.70 
19. 126 78 24 198 2.40 0.90 80 26 193 2.20 0.90 
20 504 97 19 181 2.20 0.40 133 18 177 2.60 0.80 
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TABLE-30 (a) 
LABORATORY AND RADIOLOGICAL INVESTIGATIONS (OUT 
PATIENTS) 
 
 
Sl. 
No. 
 
OP No. 
RA 
Factor 
(IU/ 
ml) 
ASO 
titre 
(IU/ 
ml) 
C- 
reative 
protin 
(mg/dl) 
 
Radiological finding 
1 34781 16.7 76.4 4.9 Spondylotic changes L2 to L4 
2 35245 18.1 64.0 1.8 Spondylotic changes L1 to L4 
3 35281 19.0 49 5.5 Spondylotic changes L3 to L5 
4 35574 14.1 90.1 4.7 Spondylotic changes L3 to L4 
5. 40506 10.9 87.3 3.5 Spondylotic changes L3 to L5 
6 42877 12.3 79.8 2.6 Spondylotic changes L5 to S1 
7 46407 17.5 80.7 2.8 Spondylotic changes L3 to L5 
8 47318 17 79.7 2.5 Spondylotic changes L2 to L5 
9 48538 19.1 88.4 2.2 Spondylotic changes L4 to S1 
10 51412 6.6 90.3 1.6 Spondylotic changes L1 to L4 
11 62571 9.3 91.2 2.3 Spondylotic changes L3 to L4 
12 63624 8.1 74.0 3.4 Spondylotic changes L5 to S1 
13 64180 10 93.0 5.4 Spondylotic changes L4 to L5 
14 70364 16.3 100.0 4.5 Spondylotic changes L2 to L5 
15 106698 15.6 88.0 2.7 Spondylotic changes L3 to L5 
16 108637 12.4 90.7 1.6 Spondylotic changes L3 to L5 
17 3316 16 111.0 2.9 Spondylotic changes L3 to L5 
18 4418 18.4 80.1 4.0 Spondylotic changes L2 to L4 
19 7908 13.7 104.0 3.1 Spondylotic changes L3 to L5 
20 9165 12.6 91.2 4.2 Spondylotic changes L3 to L5 
 
Reference Range: 
Rheumatoid Factor: Upto 20 IU/ml Serum for ASO: Upto 200IU/ml CRP: Upto 6 
mg/l 
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TABLE-30 (b) 
LABORATORY AND RADIOLOGICAL INVESTIGATIONS (IN PATIENTS) 
 
Sl. 
No. 
IP No. 
RA 
Factor 
(IU/ 
ml) 
ASO 
titre 
(IU/ 
ml) 
C- 
reative 
protin 
(mg/dl) 
Radiological finding 
1. 1503 7.4 100.9 2.9 Spondylotic changes L4 to L5 
2. 1588 10.4 69.9 4.5 Spondylotic changes L3 to L5 
3. 1794 15.7 80.0 3.0 Spondylotic changes L3 to L5 
4. 1811 1.30 40.0 4.0 Spondylotic changes L2 to L5 
5. 1892 7.0 79.8 5.0 Spondylotic changes L3 to L4 
6. 1956 9.2 61.1 3.2 Spondylotic changes L3 to L5 
7. 2042 5.6 90.2 5.3 Spondylotic changes L3 to L4 
8. 2043 13.1 76.8 2.4 Spondylotic changes L3 to L5 
9. 2784 6.9 69.5 3.1 Spondylotic changes L3 to L5 
10. 2799 4.1 71.0 6.5 Spondylotic changes L3 to L5 
11. 2832 6.3 11.0 4.8 Spondylotic changes L5 to S1 
12. 2845 6.9 60.8 5.2 Spondylotic changes L1 to L5 
13. 3079 6.6 20.0 1.8 Spondylotic changes L3 to L5 
14. 3142 7.8 81.6 4.6 Spondylotic changes L3 to L4 
15. 87 3.8 79.6 3.8 Spondylotic changes L4 to L5 
16. 101 5.4 101.4 2.7 Spondylotic changes L4 to L5 
17. 110 4.5 80.9 5.5 Spondylotic changes L4 to S1 
18. 118 7.9 70.2 3.5 Spondylotic changes L4 to L5 
19. 126 5.2 55.8 2.9 Spondylotic changes L3 to L5 
20 504 8.2 93.6 4.2 Spondylotic changes L3 to L4 
 
Reference range: 
Rheumatoid Factor: Upto 20IU/ml Serum for ASO: Upto 200 IU/ml CRP: Upto 6 
mg/L 
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TABLE-31 (a) 
BACK PAIN FUNCTIONAL SCALE SCORE VALUES (OUT PATIENTS) 
 
Sl. 
No. 
 
OP No. 
Pain score 
Before 
Treatment 
After 
Treatment 
1. 34781 30 52 
2. 35245 27 55 
3. 35281 26 57 
4. 35574 28 51 
5. 40506 22 55 
6. 42877 25 53 
7. 46407 21 59 
8. 47318 19 45 
9. 48538 27 54 
10. 51412 25 58 
11. 62571 23 52 
12. 63624 13 33 
13. 64180 16 39 
14. 70364 23 53 
15. 106698 26 51 
16. 108637 20 43 
17. 3316 10 27 
18. 4418 15 24 
19. 7908 17 47 
20 9165 24 56 
 
Interpretation: 
≤30  : No improvement / High disease activity  
31-40  : Mild improvement 
41-50 :  Moderate improvement  
51-60  : Good improvement 
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TABLE-31 (b) 
BACK PAIN FUNCTIONAL SCALE SCORE VALUES (IN PATIENTS) 
 
Sl. 
No. 
 
IP No. 
Pain score 
Before 
Treatment 
After 
Treatment 
1. 1503 28 51 
2. 1588 17 32 
3. 1794 24 53 
4. 1811 22 56 
5. 1892 23 53 
6. 1956 19 51 
7. 2042 15 54 
8. 2043 12 17 
9. 2784 11 24 
10. 2799 18 52 
11. 2832 10 58 
12. 2845 16 54 
13. 3079 27 56 
14. 3142 21 36 
15. 87 25 52 
16. 101 16 34 
17. 110 20 55 
18. 118 14 57 
19. 126 26 52 
20 504 18 33 
 
Interpretation: 
≤30 : No improvement /  High diseas activity 
 31-40 : Mild improvement 
41-50 : Moderate improvement  
51-60 : Good improvement 
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TABLE-32 (a) 
CASE SUMMARY (OUT PATIENTS) 
Sl. 
No. OP No. Name 
Age / 
Sex Occupation 
Duration of 
illness 
Treatment 
starting date 
End of 
treatment 
Total 
Days Results 
1. 34781 Murugammal 42/F Hose wife 6 Month 16.04.2018 16.05.2018 31 Good 
2. 35245 Subbulakshmi 55/F Hose wife 6 Month 18.04.2018 18.05.2018 31 Good 
3. 35281 Narayana vadivu 55/F Hose wife 3 Years 18.04.2018 19.04.2018 32 Fair 
4. 35574 Subbulakshmi 39/F Hose wife 10 Month 19.04.2018 20.05.2018 32 Good 
5. 40506 Jeya Lakshmi 45/F Coolie 1 Year 07.05.2018 07.06.2018 32 Good 
6. 42877 Kali eswari 40/F Tailor 1 ½ Years 15.05.2018 16.06.2018 32 Poor 
7. 46407 Mathiyalagan 54/M Agriculture Labour 2 Years 29.05.2018 30.06.2018 32 Fair 
8. 47318 Sanmuga Nathan 57/M Business 6 Month 01.06.2018 01.07.2018 31 Good 
9. 48538 Lakshmi 56/F Tailor 1 Year 06.06.2018 05.07.2018 30 Good 
10. 51412 Senthil kumar 48/M Agriculture Labour 8 Month 18.06.2018 17.07.2018 30 Good 
11. 62571 Kokila 31/F House wife 2 Years 27.07.2018 29.08.2018 33 Fair 
12. 63624 Murugan 38/M Coolie 4 Month 31.07.2018 30.08.2018 30 Good 
13. 64180 Mariyapan 51/M Driver 1 ½ Years 02.08.2018 01.09.2018 32 Fair 
14. 70364 Rajaguru 30/M Agricultural labour 6 Month 24.08.2018 23.09.2018 30 Good 
15. 106698 Krishnan 58/M Coolie 1 Years 25.12.2018 26.01.2019 33 Good 
16. 108637 Akni muthu 41/M Agriculture Labour 2 Years 31.12.2018 30.01.2019 31 Fair 
17. 3316 Nambi rajan 35/M Coolie 1 Year 07.01.2019 07.02.2019 31 Good 
18. 4418 Muthuvel 46/M Business 2 Years 10.01.2019 10.02.2019 31 Poor 
19. 7908 Mardisudu 46/M Tailor 3 Month 21.01.2019 19.02.2019 30 Good 
20 9165 Sankara narayanan 38/M Clerk 1 Month 24.01.2019 22.02.2019 30 Good 
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TABLE-32 (b) 
CASE SUMMARY (IN PATIENTS) 
Sl. 
No. 
 
IP No. 
 
Name 
Age / 
Sex 
 
Occupation 
Duration  
of illness 
Treatment 
starting date 
End of 
treatment 
Total Days Total 
Days 
 
Results IP OP 
1. 1503 Jayapal 69/M Coolie 1 Month 11.06.2018 12.06.2018 31 - 31 Good 
2. 1588 Senthilkumar 48/M Agricultural labour 1 Month 19.06.2018 18.07.2018 30 - 30 Good 
3. 1794 Deivakani 40/F Housewife 2 Years 16.07.2018 14.08.2018 30 - 30 Poor 
4. 1811 Abdulkabur 60/M Agricultural labour 1 Year 17.07.2018 15.08.2018 30 - 30 Fair 
5. 1892 Lakshmi 60/F Housewife 2 Month 25.07.2018 24.08.2018 31 - 31 Good 
6. 1956 Rajaguru 30/M Agricultural labour 6 Month 01.08.2018 22.08.2018 22 08 30 Good 
7. 2042 Mariyapan 51/M Driver 6 Month 09.08.2018 08.09.2018 30 - 30 Good 
8. 2043 Mariselvam 34/M Coolie 2 Month 09.08.2018 08.09.2018 30 - 30 Good 
9. 2784 Selvi 53/F Housewife 2 Years 15.11.2018 15.12.2018 31 - 31 Poor 
10. 2799 Mathiyalagan 56/M Agricultural labour 1 Month 16.11.2018 15.12.2018 30 - 30 Good 
11. 2832 Marimuthu 45/M Agricultural labour 2 Month 19.11.2018 18.12.2018 30 - 30 Good 
12. 2845 Thangam 43/F Housewife 6 Month 20.11.2018 19.12.2018 30 - 30 Good 
13. 3079 Subhiya 36/M Tailor 1 Year 14.12.2018 12.01.2019 30 - 30 Fair 
14. 3142 Sundaramal 60/F Housewife 6 Month 25.12.2018 23.01.2019 30 - 30 Fair 
15. 87 Murugan 60/M Coolie 3 Month 19.01.2019 17.02.2019 30 - 30 Good 
16. 101 Murugan 32/M Driver 8 Month 21.01.2019 19.02.2019 30 - 30 Fair 
17. 110 Murugan 60/M Agricultural labour 2 Month 21.01.2019 19.02.2019 30 - 30 Good 
18. 118 Mani 30/M Coolie 1 Month 22.01.2019 20.02.2019 30 - 30 Good 
19. 126 Umayar 48/M Coolie 4 Month 24.01.2019 22.02.2019 30 - 30 Fair 
20 504 Boopathi raja 56/M Driver 2 Years 27.02.2019 31.03.2019 33 - 33 Poor 
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MRI REPORTS 
 
IP No.1588Patient Name: Mr.SENTHIL KUMAR(48/M) 
    
 
 
IP No.8073Patient Name: Mr.MANI(30/M) 
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IP No.1503Patient Name: Mr.JAYAPAUL(60/M) 
 
   
 
IP No.2042 Patient Name: Mr.MARIYAPAN(51/M) 
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OP No.3316 Patient Name: Mr.NAMBIRAJAN(35/M) 
 
    
 
 
IP No.126Mr. UMAYAR(48/M) 
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IP No.2043Patient Name: Mr.MARISELVAM(34/M) 
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CHAPTER-VI 
DISCUSSION 
Thandaga Vatham described by Yugi Munivar in Yugi Vaidhiya Chinthamani-
800 is nearly correlated with Lumbar Spondylosis. For this clinical trial study totally 
40 patients were selected, 20 were treated as Out patients and 20 were treated as In 
patients with clinical trial drug MUNNAI ILAI KUDINEER 30ml twice a day for 30 
days.   The most important clinical features of Thandaga Vatham is pain in low back 
area, stiffness, restricted movements, tenderness, numbness and radiating pain. The 
diagnosis was made by Siddha and modern diagnostic tools.Institutional ethiclal 
committee clearance was obtained for this study with IEC No. (GSMC-IV-
IEC/2017/Br-I/07/29.05.2017). 
To evaluate the standardization of the trial drug, it was authenticated through 
visual inspection and organoleptic characters. To ensure safety is made through vivo 
and vitro studies. 
The observed results were discussed below: 
1. Incidence with Age Distribution: 
The disease was found to be higher in the age group of 51-60 in both OP and 
IP (OP-35% & IP-50%) 
2. Incidence with Sex Distribution: 
 60% of the Out paitents were males and 40% werefemales. 
 75% of the In patients were males and 25% werefemales. 
3. Distribution according to Kaalam: 
Greater part of the cases belonged to Pitha Kaalam which is commonly the 
period of degeneration (OP-90% & IP-85%). 
4. Distribution according to Paruva Kaalam: 
High incidence of the disease was in Elavenil Kaalam with 45% in OP and 
Muthuvenil  Kaalam with 35% in IP. 
5. Incidence withThinai: 
Most of the cases reported were from Marutham (OP-85% & IP-100%). 
6. Incidence with reference to Constitution of the Body: 
Pitha Vatha Thegi were much affected (OP-55% & IP-60%) 
7. Incidence with reference to Gunam: 
All cases had Rajo Gunam. 
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8. Incidence with reference to Religion: 
The highest incidence was found to be among Hindus (OP-95% & IP- 90%) 
9. Incidence with reference to Socio-Economic Status: 
In this clinical study most of the patients were from low income class with 
70% in IP and also from middle income class with 50% inOP. 
10. Incidence with reference to Food Habit: 
Most of the patients belong to non-vegeterian (OP-90% & IP-70%). 
11. Incidence with reference to Family History: 
Most of the patients don‟t have family history related to thisdisease(OP-85% 
& IP-85%). 
12. Incidence with reference to Occupation: 
Most of the patients strained themselves as heavy workers, lifting heavy 
weight, travelling a long distance and sitting for a long period of time. These may be 
the reasons to develop Thandaga Vatham. 
13. Incidence with reference to Aetiological Factors: 
Age, obesity and occupation were the main precipitating factors in majorityof 
cases. 
14. Incidence with reference to Mode of Onset: 
Most of the patients were observed in chronic state (OP-90% & IP-95%). 
15. Incidence with Duration of Illness: 
Majority of the cases were observed above 12 months and 1-6 months of 
duration (OP-35% & IP-50%). 
16. Incidence with Clinical Manifestation: 
100% of both OP & IP had low back pain and exacerbation of pain on 
movements. Radiating pain to lower limbs, restricted movements, stiffness, 
tenderness and numbness were present in variable number among the patients under 
study. 
17. Incidence with reference to Kanmenthiriyam: 
 Kaal was affected among 85% of OP & 100% of IP. 
 Eruvai was affected among 35% OP & 25% of IP. 
18. Incidence with reference to Gnanendrium: 
 Mei (Local heat) was affected among 25% of OP and 30% of IP. 
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19. Incidence with reference to Kosam: 
 Vignanamaya Kosam (Restriction of movements, low back pain) was affected 
in allcases. 
 Annamaya Kosam (Anorexia )was affected among 30% of OP & 25% of IP. 
20. Condition of Mukkutram: 
a) Disturbance in Vatham: 
 Koorman was affected among 10% of OP. 
 Kirukaran (Secretion of saliva) was affected among 30% of OP and 25% of IP. 
 Viyaanan (Movements, nervous functions and sensation), Samaanan 
(Regulates the digestion and controls all the other vayus) and Devathathan 
(Laziness) were affected in allcases. 
 Abaanan (Constipation) was affected among 35% of OP and 25% ofIP. 
b) Disturbance inPitham: 
 Sathagam (Wilful activities) was affected in all cases. 
 Analagam (Digestion) was affected among 30% of OP and 25% ofIP. 
 Ranjagam (Nutrition to blood) was affected among 25% of OP and 10% of IP. 
c) Disturbance inKapam: 
 Santhigam (Integrity of joints) was affected in allcases. 
 Klethagam (Lubrication of food) was affected among 30% of OP and 25% of 
IP. 
21. Incidence with reference to Udal Thathukkal: 
Saaram, Kozhuppu, Enbu were affected in all cases. Senner wasaffected 
among 25% of OP and 10% of IP. Disturbance in Saaram produce symptoms like 
lethargy and mental depression. Disturbance in senner was associated with Anemia. 
Disturbance in Kozhuppu, Enbu produce restricted movements, reduced intervertebral 
disc space, extra osteophytic changes and degenerative spondylotic changes in 
LumbarVertebrae. 
22. Incidence with reference to Envagai Thervugal: 
 In this study all cases had thontha naadi with high incidence of   Pitha Vatham 
(OP-55% &IP-60%). 
 Sparisam was affected among 25% of OP and 30% of IP. 
 Malam was affected among 35% of OP & 25% of IP. 
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23. Incidence with reference to NeerKuri: 
 Niram was affected among 30% of OP & 35% of IP. 
24. Incidence with reference to Neikuri: 
Majority of cases showed the neikuri as spreading like snake, when the oil is 
dropped into the urine indicating the predominance of Vatha neer (OP-70% & IP- 
65%). 
25. Incidence with reference to Radiological Studies: 
From the X-Ray of Lumbar spine (AP & Lateral view) all the cases had 
degenerative spondylotic changes. Reduced lordosis was found among 10% of IP. 
Reduced intervertebral disc space found among 10% of OP and 15% of IP. After 
treatment no changes is noted in X-Rays. 
26 (a) Assessment of Outcome-Cardinal Signs 
After treatment, the clinical trial drug showed significant effect in improving 
the grades of cardinal signs of Out patients - low back pain, radiating pain, restricted 
movement, stiffness, tenderness and numbness at the high level of significance at 
P<0.001, 0.001, 0.01, 0.05, 0.001, 0.005respectively. 
After treatment, the clinical trial drug showed significant improvements in the 
grades of cardinal signs of In patients - low back pain, radiating pain, restricted 
movements, stiffness, tenderness and numbness at the high level of significance at 
P<0.001, 0.001, 0.0001, 0.01, 0.05, 0.05respectively. 
26 (b) Range of Motion 
After treatment, range of movements score showed significant improvement 
among Out patient at the high level of significance at P<0.001. 
After treatment, range of movements score showed significant improvements 
among In patients at the high level of significance at P<0.001. 
26 (c) Back Pain Functional Scale Score 
After treatment 65% of OP and 70% of IP had good improvement. 15% of OP 
had moderate improvement. 10% of OP and 20% of IP had mild improvement. 
Bio Statistical analysis 
The BPFSS, on after treatment show a strong evidence, that the clinical trial 
drug among the Out patients showed a positive relationship and is considered to be 
extremely statistically significant at P value less than 0.001 (t=18.1542 & 95% of 
confidenceinterval). 
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The BPFSS, on after treatment show a strong evidence, that the clinical trial 
drug among the In patients showed a positive relationship and is considered to be 
extremely statistically significant at P value less than 0.001(t=10.9651 & 95% of 
confidenceinterval). 
27. Incidence with reference toresults: 
 65% of OP and 70% of IP had good response. 
 25% of OP and 20% of IP had moderateresponse. 
 10% of both OP & IP had poorresponse. 
 It was found that the end of result showed good clinical improvement in grade 
with reduction of low back pain, numbness, and stiffness, radiating pain, 
tenderness and restrictedmovements. 
 Improvement in range of motion score and low back pain functional scale 
score is alsofound. 
The statistical analysis of the observational parameters clearly indicates that 
Munnai Ilai Kudineer is highly siginificant in the treatment of Thandaga Vatham. 
Munnai Leaves has the taste of Thuvarppu, kaippu which regulates the 
vitiation of Pitham, lightens the body and maintains good health. Further it attains the 
kaarpu pirivu (section) which has the function of relieving indigestion, flatulence and 
constipation. 
Leaves contains Verbascoside, Premcoryoside, Premnine, Premnazole, 
Premnenol, Premnaspirodine, Iridoidglycoside, benzoic acid which has anti-
inflammatory, analgesic, anti oxidant activities. They are hepatoprotective and has 
anti microbial, anti bacterial and anti plasmodial potency (Jadhav Santosh et al.,). 
Further, biochemical analysis of MUNNAI ILAI KUDINEER showed the 
presence of Sulphate, Chloride (Maintaining acid base balance), Ferrous iron 
(Increases haemoglobin level),   Unsaturated compound (Building blocks of proteins) 
and aminoacids. 
On pharmacological analysis, the anti-inflammatory and analgesic activity is 
due to β-sitosterol which blocks formation of prostacyclin, they inhibit cyclo 
oxygenase (COX) the enzyme that makes Prostaglandins (PGs) the flavonoids also 
inhibits the pain perception by inhibiting prostaglandins. Peripheral pain receptors to 
send a signal from the central nervoussystem. 
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Acute oral toxicity of Munnai leaves ethanolic extract given to wistar rats at 
the dose of 100mg/kg bw did not produce toxicities. 
Infusion is the process of extracting chemical compounds or flavors from plant 
material in a solvent such as water, by allowing the material to remain suspended in 
the solvent overtime. Further, the herbs are immediately available for assimilation  
into the blood stream, glands and organs. Even patients with poor digestion and 
assimilation gets significant bio availability. So the constituents within the herb 
promote healing as well as maintenance of health (Anna Szymczycha-Madeja et al.,). 
So its best to uptake Munnai leaves asinfusion. 
Thus Munnai Ilai Kudineer by virtue of its actions mentioned previously help 
in reducing the cardinal signs of lumbar spondylosis and prevents further 
degeneration. 
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CHAPTER-VII 
SUMMARY 
An open labeled Non randomized clinical study on “THANDAGA 
VATHAM” with reference to its aetiology, pathogenesis, clinical features, diagnosis, 
investigations and treatment were conducted at Department of Pothu Maruthuvam, 
Government Siddha Medical College Hospital,Palayamkottai.This clinical study of 
Thandaga Vatham is done on the basis of reference inYugi Vaidhya Chinthamani-
800, which is correlated in modern medicine is  Lumbar Spondylosis. 
The trial drug chosen for the clinical study is MUNNAI ILAI KUDINEER  
Dosage 30ml twice daily after food for 30 days (Ref.: Gunapadam Mooligai Vagupu, 
Page No.779-780). 
A number of literatures were collected regarding Siddha as well as modern 
system of medicine.For this study, out of 40 patients, 20 patients were diagnosed 
clinically and admitted in the In patients ward and treated with trial medicines. 
Another 20 as Out patients 
The patient treated with the trial drug MUNNAI ILAI KUDINEER twice a 
day daily for 30 days.Siddha diagnosis is achieved with the help of Envagai 
Thervugal and Ezhu Udal Thathukkal. 
Since, Thandaga Vatham is a chronic disease, it requires treatement for 
minimum thirty days to minimize severe pain, tenderness, swelling and stiffness 
further the patient is advised to follow up the treatment in Out patients 
department.From this study the following datas are clear. The disease has increased 
incidence among individuals with more physical activity, higher BMI scores. Despite 
marked variability within the population, men appear to have more significant 
degenerative changes than women. Maximum incidence was in Kaba Kaalam. 
Clinically marked reduction in the symptoms along with increase sense of well being, 
improvement in the grade of cardinal signs and range of motion, decrease in the 
“BACK PAIN FUNCTIONAL ASSESSMENT SCORE” was noted. 
The patients were observed for a period of 3 months during and after the 
course of treatment. No signs of complications were reported. Clinically no toxic 
effects were noticed during the treatment period. The Pharmacological evaluation and 
biochemical analysis of MUNNAI ILAI KUDINEER were also carried out results of 
this clinical trial study statistically  and  significantly  proved. 
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CHAPTER-VIII 
CONCLUSION 
Thandaga Vatham is mentioned in Yugi Vaidhya Chinthamani-800 which is 
correlated with the clinical signs and symptoms are smillerly Lumbar spondylosis. 
The people suffering from lumbar spondylosis were increasing day by day even at the 
age of 30-60. The disease Thandaga Vatham cases treated with Munnai Ilai Kudineer 
and  well analysed under Siddha and modern clinical parameters. In clinically 
MUNNAI ILAI KUDINEER highly response in 67.5%, showed good response; 
22.5% showed moderate response; and poor response was 10%.By clinicaly  pain 
score and flexibility were improved in  case of  lumbar spondylosis. 
The review literature in siddha and modern journals are confirmed the action 
was MUNNAI ILAI KUDINEER was highly therapeutic effect of pain management 
in thandaga Vatham. In adition that invivo and invitro also detramined in MUNNAI 
ILAI KUDINEER is proved in analgesic (Table 5.1) , anti inflammatory action (Table 
5.2), and  anti microbial action (Table 5.5). 
The presence of sulphate, chloride, ferrous iron, unsaturated compound and 
amino acid were found in Bio chemical analysis. 
No toxic effect were noticed during the treatment period. It was confumed by 
Invitro – In vivo and acute and sub acute toxicity studies. 
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 ANNEXURE-I 
PREPARATION AND PROPERTIES OF TRIAL MEDICINE 
Le<je!-jz!GcfQi<< Q << Q << Q < 
(Reference: Gunapadam Mooligai Part-I Page No.779-780) 
Tamil 
Name 
Botanical Name 
(Family) 
Phytochemica
ls 
Action 
Thera           
peutic 
uses 
Amount 
Leaves 
of 
Munnai 
Prema corymbosa 
(VERBENACEAE) 
Verbascoside, 
Iridoid 
glycoside 
Premcoryoside 
Premnine, 
Premnazole 
Premnenol 
Premna 
spirodiene . 
Anti- 
inflammatory, 
Anti-oxidant, 
Anti-analgesic 
Vatha 
disease 
7.5gms 
 
 
PURIFICATIONS OF DRUG: 
Fresh leaves of Munnai  is cleaned to remove dust and impurities. Then, is 
made dry in shade. 
METHOD OF PREPARATION: 
Fresh leaves of  Munnai  is cleaned  and made  drying  in shade. Then it is 
made into coarse powder. Now add  7.5gms of powder is boiled and make kashayam 
to dispensing for patients.    
DOSE : 30 ML Twise\day 
Le<je!-jz;<<< !
! Sju!!! ;! Kui<h<H?!jgh<H< < << < << < < !
! ke<jl<<< ! ;! ouh<hl<< << << <!
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Le<je!<<< . Premna corymbosa 
 
PREPARATION OF  MUNNAI ILAI KUDINEER 
DRIED LEAVES 
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